JP6007417B2 - 新規glp−1受容体安定剤および調節剤 - Google Patents
新規glp−1受容体安定剤および調節剤 Download PDFInfo
- Publication number
- JP6007417B2 JP6007417B2 JP2014513706A JP2014513706A JP6007417B2 JP 6007417 B2 JP6007417 B2 JP 6007417B2 JP 2014513706 A JP2014513706 A JP 2014513706A JP 2014513706 A JP2014513706 A JP 2014513706A JP 6007417 B2 JP6007417 B2 JP 6007417B2
- Authority
- JP
- Japan
- Prior art keywords
- independently
- alkyl
- ring
- atom
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 title claims description 47
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title claims description 45
- 239000003381 stabilizer Substances 0.000 title description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 549
- 150000001875 compounds Chemical class 0.000 claims description 400
- -1 hydroxy, methyl Chemical group 0.000 claims description 283
- 125000000217 alkyl group Chemical group 0.000 claims description 182
- 125000003118 aryl group Chemical group 0.000 claims description 109
- 125000003545 alkoxy group Chemical group 0.000 claims description 95
- 125000001072 heteroaryl group Chemical group 0.000 claims description 87
- 125000000623 heterocyclic group Chemical group 0.000 claims description 85
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 78
- 125000006413 ring segment Chemical group 0.000 claims description 78
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 75
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 71
- 239000000203 mixture Substances 0.000 claims description 61
- 150000003839 salts Chemical class 0.000 claims description 56
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 53
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 51
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 49
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 43
- 229910052799 carbon Inorganic materials 0.000 claims description 34
- 102000005962 receptors Human genes 0.000 claims description 31
- 108020003175 receptors Proteins 0.000 claims description 31
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 30
- 125000004043 oxo group Chemical group O=* 0.000 claims description 29
- OSDBJMYIUDLIRI-UHFFFAOYSA-N oxo-[[1-[[4-[[4-(oxoazaniumylmethylidene)pyridin-1-yl]methoxy]cyclohexyl]oxymethyl]pyridin-4-ylidene]methyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C1=CC(=C[NH+]=O)C=CN1COC1CCC(OCN2C=CC(=C[NH+]=O)C=C2)CC1 OSDBJMYIUDLIRI-UHFFFAOYSA-N 0.000 claims description 23
- 229910052736 halogen Inorganic materials 0.000 claims description 22
- 150000002367 halogens Chemical group 0.000 claims description 22
- 230000004913 activation Effects 0.000 claims description 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 18
- 230000002159 abnormal effect Effects 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 125000002619 bicyclic group Chemical group 0.000 claims description 14
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 230000008484 agonism Effects 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 239000003085 diluting agent Substances 0.000 claims description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
- VHVGFEDTMPYCSX-UHFFFAOYSA-N [1-[[2,2-dimethyl-3-[[4-(oxoazaniumylmethylidene)pyridin-1-yl]methoxy]propoxy]methyl]pyridin-4-ylidene]methyl-oxoazanium;dichloride Chemical compound [Cl-].[Cl-].C1=CC(=C[NH+]=O)C=CN1COCC(C)(C)COCN1C=CC(=C[NH+]=O)C=C1 VHVGFEDTMPYCSX-UHFFFAOYSA-N 0.000 claims description 9
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 208000008589 Obesity Diseases 0.000 claims description 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 7
- 208000022531 anorexia Diseases 0.000 claims description 7
- 125000004980 cyclopropylene group Chemical group 0.000 claims description 7
- 206010061428 decreased appetite Diseases 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 208000004104 gestational diabetes Diseases 0.000 claims description 7
- 208000030159 metabolic disease Diseases 0.000 claims description 7
- 235000020824 obesity Nutrition 0.000 claims description 7
- 206010064720 Lack of satiety Diseases 0.000 claims description 6
- 230000009286 beneficial effect Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 5
- 125000001475 halogen functional group Chemical group 0.000 claims 16
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 claims 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 description 299
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 256
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 222
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 210
- 239000011541 reaction mixture Substances 0.000 description 186
- 239000000243 solution Substances 0.000 description 119
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 98
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 84
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 78
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 78
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 73
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 72
- 125000005842 heteroatom Chemical group 0.000 description 64
- 238000003756 stirring Methods 0.000 description 63
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- 125000005843 halogen group Chemical group 0.000 description 53
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 52
- 238000004587 chromatography analysis Methods 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 48
- 238000005481 NMR spectroscopy Methods 0.000 description 47
- 239000002904 solvent Substances 0.000 description 44
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 41
- 239000007787 solid Substances 0.000 description 41
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 40
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 39
- 238000002953 preparative HPLC Methods 0.000 description 36
- 239000012044 organic layer Substances 0.000 description 33
- 239000012267 brine Substances 0.000 description 32
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 32
- 238000000746 purification Methods 0.000 description 30
- 229910052717 sulfur Inorganic materials 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 29
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical group CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 29
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 150000002148 esters Chemical class 0.000 description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- 239000000651 prodrug Substances 0.000 description 25
- 229940002612 prodrug Drugs 0.000 description 25
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 24
- 235000011054 acetic acid Nutrition 0.000 description 23
- 239000011734 sodium Substances 0.000 description 23
- 239000007821 HATU Substances 0.000 description 22
- 150000001412 amines Chemical class 0.000 description 22
- 239000003153 chemical reaction reagent Substances 0.000 description 22
- 239000012467 final product Substances 0.000 description 22
- 239000012453 solvate Substances 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 21
- 229910052760 oxygen Inorganic materials 0.000 description 21
- 239000000843 powder Substances 0.000 description 21
- ZRVIYEJYXIDATJ-UHFFFAOYSA-N 4-Heptyloxybenzoic acid Chemical compound CCCCCCCOC1=CC=C(C(O)=O)C=C1 ZRVIYEJYXIDATJ-UHFFFAOYSA-N 0.000 description 20
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 20
- 239000002253 acid Substances 0.000 description 20
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 20
- 239000012071 phase Substances 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 125000004432 carbon atom Chemical group C* 0.000 description 19
- 239000012043 crude product Substances 0.000 description 19
- 125000002971 oxazolyl group Chemical group 0.000 description 19
- 239000000741 silica gel Substances 0.000 description 19
- 229910002027 silica gel Inorganic materials 0.000 description 19
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 17
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 17
- 102100040918 Pro-glucagon Human genes 0.000 description 17
- 238000004440 column chromatography Methods 0.000 description 17
- 125000001715 oxadiazolyl group Chemical group 0.000 description 17
- 125000000714 pyrimidinyl group Chemical group 0.000 description 17
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 16
- 125000003226 pyrazolyl group Chemical group 0.000 description 16
- 125000001425 triazolyl group Chemical group 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 14
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 14
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 14
- 239000004305 biphenyl Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 101100317378 Mus musculus Wnt3 gene Proteins 0.000 description 13
- 239000013058 crude material Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 12
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 12
- 235000010290 biphenyl Nutrition 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 12
- 239000000556 agonist Substances 0.000 description 11
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 10
- RWONLGIMUWOZCT-UHFFFAOYSA-N 4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(O)=O)C=C1 RWONLGIMUWOZCT-UHFFFAOYSA-N 0.000 description 10
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 10
- 108010011459 Exenatide Proteins 0.000 description 10
- 235000019253 formic acid Nutrition 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 9
- 229910052794 bromium Inorganic materials 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 230000002209 hydrophobic effect Effects 0.000 description 9
- 125000004076 pyridyl group Chemical group 0.000 description 9
- KAWNUDYZAZJFQG-UHFFFAOYSA-N 4-(4-methylphenyl)benzohydrazide Chemical compound C1=CC(C)=CC=C1C1=CC=C(C(=O)NN)C=C1 KAWNUDYZAZJFQG-UHFFFAOYSA-N 0.000 description 8
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 150000001721 carbon Chemical group 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- PYFSLJVSCGXYAJ-UHFFFAOYSA-N methyl 2-hydroxy-4-[[3-(2-hydroxyphenyl)phenyl]sulfonylamino]benzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=CC=CC(C=2C(=CC=CC=2)O)=C1 PYFSLJVSCGXYAJ-UHFFFAOYSA-N 0.000 description 8
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 229910000104 sodium hydride Inorganic materials 0.000 description 8
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 7
- OLFHWAPSVHCTJS-UHFFFAOYSA-N 2-methoxy-4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(O)=O)C(OC)=C1 OLFHWAPSVHCTJS-UHFFFAOYSA-N 0.000 description 7
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 7
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 7
- 108010019598 Liraglutide Proteins 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 108090000445 Parathyroid hormone Proteins 0.000 description 7
- 125000002252 acyl group Chemical group 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 229960001519 exenatide Drugs 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 125000001544 thienyl group Chemical group 0.000 description 7
- 125000004149 thio group Chemical group *S* 0.000 description 7
- MWEPEELWZJPSNQ-UHFFFAOYSA-N 2-[(4-heptoxyphenyl)methyl]-3h-benzimidazole-5-carbaldehyde Chemical compound C1=CC(OCCCCCCC)=CC=C1CC1=NC2=CC=C(C=O)C=C2N1 MWEPEELWZJPSNQ-UHFFFAOYSA-N 0.000 description 6
- HXAKXGYHLSQZAT-UHFFFAOYSA-N 4-[2-(4-bromophenyl)-1,3-oxazol-4-yl]benzonitrile Chemical compound C1=CC(Br)=CC=C1C1=NC(C=2C=CC(=CC=2)C#N)=CO1 HXAKXGYHLSQZAT-UHFFFAOYSA-N 0.000 description 6
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 6
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 6
- DRNXUSJEOMZAQL-UHFFFAOYSA-N 5-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxylic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(O)=O)N=C1 DRNXUSJEOMZAQL-UHFFFAOYSA-N 0.000 description 6
- QKXKSQXNSFZTLA-UHFFFAOYSA-N 6-heptoxypyridine-3-carboxylic acid Chemical compound CCCCCCCOC1=CC=C(C(O)=O)C=N1 QKXKSQXNSFZTLA-UHFFFAOYSA-N 0.000 description 6
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 6
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 6
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 108010004367 lixisenatide Proteins 0.000 description 6
- 229960001093 lixisenatide Drugs 0.000 description 6
- DKUMFPWSHAXXPC-UHFFFAOYSA-N n'-amino-4-(4-methylphenyl)benzenecarboximidamide Chemical compound C1=CC(C)=CC=C1C1=CC=C(C(N)=NN)C=C1 DKUMFPWSHAXXPC-UHFFFAOYSA-N 0.000 description 6
- 229920000728 polyester Polymers 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 description 6
- 125000000335 thiazolyl group Chemical group 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- ZCSKJKCNRUYYNM-UHFFFAOYSA-N 2-[[2-[(4-heptoxyphenyl)methyl]-3h-benzimidazol-5-yl]methyl-[4-[[2-(4-methoxyphenyl)acetyl]amino]benzoyl]amino]acetic acid Chemical compound C1=CC(OCCCCCCC)=CC=C1CC(NC1=C2)=NC1=CC=C2CN(CC(O)=O)C(=O)C(C=C1)=CC=C1NC(=O)CC1=CC=C(OC)C=C1 ZCSKJKCNRUYYNM-UHFFFAOYSA-N 0.000 description 5
- RZOCCLOTCXINRG-UHFFFAOYSA-N 4-(4-methylphenyl)benzoic acid Chemical compound C1=CC(C)=CC=C1C1=CC=C(C(O)=O)C=C1 RZOCCLOTCXINRG-UHFFFAOYSA-N 0.000 description 5
- NEGDYSVDTFPAIV-UHFFFAOYSA-N 4-[2-(4-bromophenyl)-1,3-oxazol-4-yl]benzaldehyde Chemical compound C1=CC(Br)=CC=C1C1=NC(C=2C=CC(C=O)=CC=2)=CO1 NEGDYSVDTFPAIV-UHFFFAOYSA-N 0.000 description 5
- ZNSOYERXWRJJNT-UHFFFAOYSA-N 4-[[4-methoxy-2-(trifluoromethyl)phenyl]methylcarbamoyl]benzoic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(C(O)=O)C=C1 ZNSOYERXWRJJNT-UHFFFAOYSA-N 0.000 description 5
- 108010063919 Glucagon Receptors Proteins 0.000 description 5
- 102100040890 Glucagon receptor Human genes 0.000 description 5
- 108010024044 Glucagon-Like Peptide-2 Receptor Proteins 0.000 description 5
- 102000015626 Glucagon-Like Peptide-2 Receptor Human genes 0.000 description 5
- 102100036893 Parathyroid hormone Human genes 0.000 description 5
- 101150003085 Pdcl gene Proteins 0.000 description 5
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 5
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000015165 citric acid Nutrition 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 description 5
- 125000001041 indolyl group Chemical group 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 229960002701 liraglutide Drugs 0.000 description 5
- KXTNCDYLCYIQLF-UHFFFAOYSA-N n-[(4-hydroxyphenyl)methyl]-4-nitrobenzamide Chemical compound C1=CC(O)=CC=C1CNC(=O)C1=CC=C([N+]([O-])=O)C=C1 KXTNCDYLCYIQLF-UHFFFAOYSA-N 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 108010048573 taspoglutide Proteins 0.000 description 5
- 229950007151 taspoglutide Drugs 0.000 description 5
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 5
- BFEZVZBCRXRFGE-UHFFFAOYSA-N (4-formyl-3-methoxyphenyl) 4-heptoxybenzoate Chemical compound C1=CC(OCCCCCCC)=CC=C1C(=O)OC1=CC=C(C=O)C(OC)=C1 BFEZVZBCRXRFGE-UHFFFAOYSA-N 0.000 description 4
- MMOCZLVMHDJCON-UHFFFAOYSA-N (4-formylphenyl) 4-heptoxybenzoate Chemical compound C1=CC(OCCCCCCC)=CC=C1C(=O)OC1=CC=C(C=O)C=C1 MMOCZLVMHDJCON-UHFFFAOYSA-N 0.000 description 4
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 4
- RQJDUEKERVZLLU-UHFFFAOYSA-N 4-Hydroxybenzylamine Chemical compound NCC1=CC=C(O)C=C1 RQJDUEKERVZLLU-UHFFFAOYSA-N 0.000 description 4
- 101000810330 Arabidopsis thaliana Eukaryotic translation initiation factor 3 subunit E Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000008016 Eukaryotic Initiation Factor-3 Human genes 0.000 description 4
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 4
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000002837 carbocyclic group Chemical group 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- 229960004580 glibenclamide Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- ZZOAFWUWBBOZHP-UHFFFAOYSA-N methyl 5-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxylate Chemical compound C1=NC(C(=O)OC)=CC=C1NC(=O)CC1=CC=C(OC)C=C1C(F)(F)F ZZOAFWUWBBOZHP-UHFFFAOYSA-N 0.000 description 4
- 229940095102 methyl benzoate Drugs 0.000 description 4
- XSWNAJICRFPFCE-UHFFFAOYSA-N n'-hydroxy-4-(4-methylphenyl)benzenecarboximidamide Chemical compound C1=CC(C)=CC=C1C1=CC=C(C(N)=NO)C=C1 XSWNAJICRFPFCE-UHFFFAOYSA-N 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- 150000003457 sulfones Chemical class 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- FRQWVAWXEBTURS-UHFFFAOYSA-N (2-nitrophenyl) carbamate Chemical class NC(=O)OC1=CC=CC=C1[N+]([O-])=O FRQWVAWXEBTURS-UHFFFAOYSA-N 0.000 description 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 3
- QSMIUSCWMLKLJN-UHFFFAOYSA-N 2-[(4-heptoxyphenyl)methyl]-3h-benzimidazole-5-carbonitrile Chemical compound C1=CC(OCCCCCCC)=CC=C1CC1=NC2=CC=C(C#N)C=C2N1 QSMIUSCWMLKLJN-UHFFFAOYSA-N 0.000 description 3
- BUOQVRZPWJORPW-UHFFFAOYSA-N 2-[(4-hydroxyphenyl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CC=C(O)C=C1 BUOQVRZPWJORPW-UHFFFAOYSA-N 0.000 description 3
- WKSMDNSNRXWFKV-UHFFFAOYSA-N 2-[(4-iodophenyl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CC=C(I)C=C1 WKSMDNSNRXWFKV-UHFFFAOYSA-N 0.000 description 3
- ZAOJHEOIUQVOEU-UHFFFAOYSA-N 2-[4-methoxy-2-(trifluoromethyl)phenyl]acetic acid Chemical compound COC1=CC=C(CC(O)=O)C(C(F)(F)F)=C1 ZAOJHEOIUQVOEU-UHFFFAOYSA-N 0.000 description 3
- PUEUXYQWHYTZOP-UHFFFAOYSA-N 2-[[4-[[2-(4-methoxyphenyl)acetyl]amino]benzoyl]-[[4-(4-octylbenzoyl)oxyphenyl]methyl]amino]acetic acid Chemical compound C1=CC(CCCCCCCC)=CC=C1C(=O)OC(C=C1)=CC=C1CN(CC(O)=O)C(=O)C(C=C1)=CC=C1NC(=O)CC1=CC=C(OC)C=C1 PUEUXYQWHYTZOP-UHFFFAOYSA-N 0.000 description 3
- ZDYPKHAUGJLFJA-UHFFFAOYSA-N 2-[[4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoyl]-[[4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]methyl]amino]acetic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(=O)N(CC(O)=O)CC=2C=CC(=CC=2)C=2ON=C(N=2)C=2C=CC(C)=CC=2)C=C1 ZDYPKHAUGJLFJA-UHFFFAOYSA-N 0.000 description 3
- XWERWGMRTNOQSK-UHFFFAOYSA-N 2-[[4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoyl]-[[4-[4-[4-(4-methylphenyl)phenyl]-1,3-oxazol-2-yl]phenyl]methyl]amino]acetic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(=O)N(CC(O)=O)CC=2C=CC(=CC=2)C=2OC=C(N=2)C=2C=CC(=CC=2)C=2C=CC(C)=CC=2)C=C1 XWERWGMRTNOQSK-UHFFFAOYSA-N 0.000 description 3
- QMFAWRBMNIDDRV-UHFFFAOYSA-N 2-[[4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoyl]-[[4-[5-[4-(4-methylphenyl)phenyl]-1,2,4-oxadiazol-3-yl]phenyl]methyl]amino]acetic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(=O)N(CC(O)=O)CC=2C=CC(=CC=2)C=2N=C(ON=2)C=2C=CC(=CC=2)C=2C=CC(C)=CC=2)C=C1 QMFAWRBMNIDDRV-UHFFFAOYSA-N 0.000 description 3
- DQSRVWNGCNSDNE-UHFFFAOYSA-N 3-(pyridin-3-ylamino)propyl 4-[[3-(5-fluoro-2-hydroxyphenyl)phenyl]sulfonylamino]-2-hydroxybenzoate Chemical compound OC1=CC=C(F)C=C1C1=CC=CC(S(=O)(=O)NC=2C=C(O)C(C(=O)OCCCNC=3C=NC=CC=3)=CC=2)=C1 DQSRVWNGCNSDNE-UHFFFAOYSA-N 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- HIKILRNGPFKUBC-UHFFFAOYSA-N 4-[2-[4-methoxy-2-(trifluoromethyl)anilino]-2-oxoethyl]benzoic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1NC(=O)CC1=CC=C(C(O)=O)C=C1 HIKILRNGPFKUBC-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 3
- 102000051325 Glucagon Human genes 0.000 description 3
- 108060003199 Glucagon Proteins 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- FEXQDZTYJVXMOS-UHFFFAOYSA-N Isopropyl benzoate Chemical compound CC(C)OC(=O)C1=CC=CC=C1 FEXQDZTYJVXMOS-UHFFFAOYSA-N 0.000 description 3
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940100389 Sulfonylurea Drugs 0.000 description 3
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 3
- 229940123464 Thiazolidinedione Drugs 0.000 description 3
- 101001060278 Xenopus laevis Fibroblast growth factor 3 Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 150000004982 aromatic amines Chemical class 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 229940084891 byetta Drugs 0.000 description 3
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960002449 glycine Drugs 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 3
- 239000000859 incretin Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 229960003105 metformin Drugs 0.000 description 3
- QSRRZKPKHJHIRB-UHFFFAOYSA-N methyl 4-[(2,5-dichloro-4-methylthiophen-3-yl)sulfonylamino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=C(Cl)SC(Cl)=C1C QSRRZKPKHJHIRB-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 238000012916 structural analysis Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- FHLXUWOHGKLDNF-UHFFFAOYSA-N (2-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=CC=C1OC(Cl)=O FHLXUWOHGKLDNF-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 2
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 2
- OLKQIWCQICCYQS-UHFFFAOYSA-N 2-(4-methoxyphenyl)acetamide Chemical compound COC1=CC=C(CC(N)=O)C=C1 OLKQIWCQICCYQS-UHFFFAOYSA-N 0.000 description 2
- CXJOONIFSVSFAD-UHFFFAOYSA-N 2-(4-methoxyphenyl)acetyl chloride Chemical compound COC1=CC=C(CC(Cl)=O)C=C1 CXJOONIFSVSFAD-UHFFFAOYSA-N 0.000 description 2
- OOOVZWNXURPMLE-UHFFFAOYSA-N 2-[[2-methoxy-4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoyl]-[[4-[4-(4-methylphenyl)benzoyl]oxyphenyl]methyl]amino]acetic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1CC(=O)NC(C=C1OC)=CC=C1C(=O)N(CC(O)=O)CC(C=C1)=CC=C1OC(=O)C1=CC=C(C=2C=CC(C)=CC=2)C=C1 OOOVZWNXURPMLE-UHFFFAOYSA-N 0.000 description 2
- RBTFYTLWAFMIMV-UHFFFAOYSA-N 2-[[4-(4-heptoxybenzoyl)oxyphenyl]methyl-[4-[[2-(3-methoxy-4-methylphenyl)acetyl]amino]benzoyl]amino]acetic acid Chemical compound C1=CC(OCCCCCCC)=CC=C1C(=O)OC(C=C1)=CC=C1CN(CC(O)=O)C(=O)C(C=C1)=CC=C1NC(=O)CC1=CC=C(C)C(OC)=C1 RBTFYTLWAFMIMV-UHFFFAOYSA-N 0.000 description 2
- BTXMLQLAPDNMCQ-UHFFFAOYSA-N 2-[[4-(4-heptoxybenzoyl)oxyphenyl]methyl-[4-[[2-(4-methoxyphenyl)acetyl]amino]benzoyl]amino]acetic acid Chemical compound C1=CC(OCCCCCCC)=CC=C1C(=O)OC(C=C1)=CC=C1CN(CC(O)=O)C(=O)C(C=C1)=CC=C1NC(=O)CC1=CC=C(OC)C=C1 BTXMLQLAPDNMCQ-UHFFFAOYSA-N 0.000 description 2
- ORCLIPKOAYOONY-UHFFFAOYSA-N 2-[[4-(4-heptoxybenzoyl)oxyphenyl]methyl-[4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoyl]amino]acetic acid Chemical compound C1=CC(OCCCCCCC)=CC=C1C(=O)OC(C=C1)=CC=C1CN(CC(O)=O)C(=O)C(C=C1)=CC=C1NC(=O)CC1=CC=C(OC)C=C1C(F)(F)F ORCLIPKOAYOONY-UHFFFAOYSA-N 0.000 description 2
- FMMBAJKHOCXKOD-UHFFFAOYSA-N 2-[[4-(4-heptoxybenzoyl)oxyphenyl]methyl-[4-[[4-methoxy-2-(trifluoromethyl)phenyl]methylcarbamoyl]benzoyl]amino]acetic acid Chemical compound C1=CC(OCCCCCCC)=CC=C1C(=O)OC(C=C1)=CC=C1CN(CC(O)=O)C(=O)C1=CC=C(C(=O)NCC=2C(=CC(OC)=CC=2)C(F)(F)F)C=C1 FMMBAJKHOCXKOD-UHFFFAOYSA-N 0.000 description 2
- DSXGDXAXUFZOHO-UHFFFAOYSA-N 2-[[4-(4-heptoxybenzoyl)oxyphenyl]methyl-[5-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carbonyl]amino]acetic acid Chemical compound C1=CC(OCCCCCCC)=CC=C1C(=O)OC(C=C1)=CC=C1CN(CC(O)=O)C(=O)C(N=C1)=CC=C1NC(=O)CC1=CC=C(OC)C=C1C(F)(F)F DSXGDXAXUFZOHO-UHFFFAOYSA-N 0.000 description 2
- FDYBTQVTQMUDCF-UHFFFAOYSA-N 2-[[4-[2-(4-bromophenyl)-1,3-oxazol-4-yl]phenyl]methyl-[4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoyl]amino]acetic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(=O)N(CC(O)=O)CC=2C=CC(=CC=2)C=2N=C(OC=2)C=2C=CC(Br)=CC=2)C=C1 FDYBTQVTQMUDCF-UHFFFAOYSA-N 0.000 description 2
- CDAKEGHTGXAOPN-UHFFFAOYSA-N 2-[[4-[[2-(4-methoxyphenyl)acetyl]amino]benzoyl]-[[4-(4-nonoxybenzoyl)oxyphenyl]methyl]amino]acetic acid Chemical compound C1=CC(OCCCCCCCCC)=CC=C1C(=O)OC(C=C1)=CC=C1CN(CC(O)=O)C(=O)C(C=C1)=CC=C1NC(=O)CC1=CC=C(OC)C=C1 CDAKEGHTGXAOPN-UHFFFAOYSA-N 0.000 description 2
- MDLWWYHWVFYHAS-UHFFFAOYSA-N 2-[[4-[[2-(4-methoxyphenyl)acetyl]amino]benzoyl]-[[4-(4-phenylbenzoyl)oxyphenyl]methyl]amino]acetic acid Chemical compound C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(=O)N(CC(O)=O)CC=2C=CC(OC(=O)C=3C=CC(=CC=3)C=3C=CC=CC=3)=CC=2)C=C1 MDLWWYHWVFYHAS-UHFFFAOYSA-N 0.000 description 2
- IPLKVANYDFNCIK-UHFFFAOYSA-N 2-[[4-[[2-(4-methoxyphenyl)acetyl]amino]benzoyl]-[[4-[4-(3-methylbutoxy)benzoyl]oxyphenyl]methyl]amino]acetic acid Chemical compound C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(=O)N(CC(O)=O)CC=2C=CC(OC(=O)C=3C=CC(OCCC(C)C)=CC=3)=CC=2)C=C1 IPLKVANYDFNCIK-UHFFFAOYSA-N 0.000 description 2
- KYSNCUXUSKEDKQ-UHFFFAOYSA-N 2-[[4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoyl]-[[4-[3-[4-(4-methylphenyl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]methyl]amino]acetic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(=O)N(CC(O)=O)CC=2C=CC(=CC=2)C=2ON=C(N=2)C=2C=CC(=CC=2)C=2C=CC(C)=CC=2)C=C1 KYSNCUXUSKEDKQ-UHFFFAOYSA-N 0.000 description 2
- XPIKPIQHPFHYQK-UHFFFAOYSA-N 2-[[4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoyl]-[[4-[3-[4-(4-methylphenyl)phenyl]-1h-1,2,4-triazol-5-yl]phenyl]methyl]amino]acetic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(=O)N(CC(O)=O)CC=2C=CC(=CC=2)C=2NN=C(N=2)C=2C=CC(=CC=2)C=2C=CC(C)=CC=2)C=C1 XPIKPIQHPFHYQK-UHFFFAOYSA-N 0.000 description 2
- VQUUGQJCPMMHRT-UHFFFAOYSA-N 2-[[4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoyl]-[[4-[4-(4-methylphenyl)benzoyl]oxyphenyl]methyl]amino]acetic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(=O)N(CC(O)=O)CC=2C=CC(OC(=O)C=3C=CC(=CC=3)C=3C=CC(C)=CC=3)=CC=2)C=C1 VQUUGQJCPMMHRT-UHFFFAOYSA-N 0.000 description 2
- YQXMEJBEUCWHTA-UHFFFAOYSA-N 2-[[4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoyl]-[[4-[5-(4-methylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]amino]acetic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(=O)N(CC(O)=O)CC=2C=CC(=CC=2)C=2N=C(ON=2)C=2C=CC(C)=CC=2)C=C1 YQXMEJBEUCWHTA-UHFFFAOYSA-N 0.000 description 2
- SJHWXHFDKQLXBI-UHFFFAOYSA-N 2-[[4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoyl]-[[4-[5-[4-(4-methylphenyl)phenyl]-1,3,4-oxadiazol-2-yl]phenyl]methyl]amino]acetic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(=O)N(CC(O)=O)CC=2C=CC(=CC=2)C=2OC(=NN=2)C=2C=CC(=CC=2)C=2C=CC(C)=CC=2)C=C1 SJHWXHFDKQLXBI-UHFFFAOYSA-N 0.000 description 2
- DYHBVEQMSCUSKN-UHFFFAOYSA-N 2-aminoacetic acid;2-chloro-2-methylpropane Chemical compound CC(C)(C)Cl.NCC(O)=O DYHBVEQMSCUSKN-UHFFFAOYSA-N 0.000 description 2
- HCZOGIZYAVELNA-UHFFFAOYSA-N 2-bromo-1-[4-(4-methylphenyl)phenyl]ethanone Chemical compound C1=CC(C)=CC=C1C1=CC=C(C(=O)CBr)C=C1 HCZOGIZYAVELNA-UHFFFAOYSA-N 0.000 description 2
- BNGPVKSKKYIJCR-UHFFFAOYSA-N 2-chloro-1,3-dimethylimidazolidine;hydrochloride Chemical compound [Cl-].CN1CC[NH+](C)C1Cl BNGPVKSKKYIJCR-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- VWLLPPSBBHDXHK-UHFFFAOYSA-N 3,4-diaminobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1N VWLLPPSBBHDXHK-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- QIBWMVSMTSYUSK-UHFFFAOYSA-N 4-(4-methylphenyl)benzonitrile Chemical compound C1=CC(C)=CC=C1C1=CC=C(C#N)C=C1 QIBWMVSMTSYUSK-UHFFFAOYSA-N 0.000 description 2
- ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 description 2
- RHTBNDNXCRUJQG-UHFFFAOYSA-N 4-[2-(4-bromophenoxy)-1-hydroxyethyl]benzaldehyde Chemical compound C=1C=C(C=O)C=CC=1C(O)COC1=CC=C(Br)C=C1 RHTBNDNXCRUJQG-UHFFFAOYSA-N 0.000 description 2
- USZATBBIZIFMHS-UHFFFAOYSA-N 4-[[[4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoyl]-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]methyl]benzoic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(=O)N(CC(=O)OC(C)(C)C)CC=2C=CC(=CC=2)C(O)=O)C=C1 USZATBBIZIFMHS-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- ZRWNRAJCPNLYAK-UHFFFAOYSA-N 4-bromobenzamide Chemical compound NC(=O)C1=CC=C(Br)C=C1 ZRWNRAJCPNLYAK-UHFFFAOYSA-N 0.000 description 2
- WBIZZNFQJPOKDK-UHFFFAOYSA-N 4-hydroxy-2-methoxybenzaldehyde Chemical compound COC1=CC(O)=CC=C1C=O WBIZZNFQJPOKDK-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 2
- ZQLDNJKHLQOJGE-UHFFFAOYSA-N 4-octylbenzoic acid Chemical compound CCCCCCCCC1=CC=C(C(O)=O)C=C1 ZQLDNJKHLQOJGE-UHFFFAOYSA-N 0.000 description 2
- JPVUWCPKMYXOKW-UHFFFAOYSA-N 4-phenylbenzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1C1=CC=CC=C1 JPVUWCPKMYXOKW-UHFFFAOYSA-N 0.000 description 2
- 125000001572 5'-adenylyl group Chemical group C=12N=C([H])N=C(N([H])[H])C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 description 2
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 2
- 101800004295 Glucagon-like peptide 1(7-36) Proteins 0.000 description 2
- HNSCCNJWTJUGNQ-UHFFFAOYSA-N Glyclopyramide Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)NC(=O)NN1CCCC1 HNSCCNJWTJUGNQ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 102400000319 Oxyntomodulin Human genes 0.000 description 2
- 101800001388 Oxyntomodulin Proteins 0.000 description 2
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 2
- 229940126033 PPAR agonist Drugs 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960001466 acetohexamide Drugs 0.000 description 2
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 2
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 150000001499 aryl bromides Chemical class 0.000 description 2
- 150000001500 aryl chlorides Chemical class 0.000 description 2
- 150000007860 aryl ester derivatives Chemical class 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 2
- 125000004321 azepin-2-yl group Chemical group [H]N1C([H])=C([H])C([H])=C([H])C([H])=C1* 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 229960003362 carbutamide Drugs 0.000 description 2
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960001761 chlorpropamide Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- 125000002993 cycloalkylene group Chemical group 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 125000005879 dioxolanyl group Chemical group 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- PTCGDEVVHUXTMP-UHFFFAOYSA-N flutolanil Chemical compound CC(C)OC1=CC=CC(NC(=O)C=2C(=CC=CC=2)C(F)(F)F)=C1 PTCGDEVVHUXTMP-UHFFFAOYSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 108010049869 gastric inhibitory polypeptide (1-42) Proteins 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960000346 gliclazide Drugs 0.000 description 2
- 229960004346 glimepiride Drugs 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229950002888 glyclopyramide Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- XKPJKVVZOOEMPK-UHFFFAOYSA-M lithium;formate Chemical compound [Li+].[O-]C=O XKPJKVVZOOEMPK-UHFFFAOYSA-M 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- PFYHAAAQPNMZHO-UHFFFAOYSA-N methoxy-benzoic acid methyl ester Natural products COC(=O)C1=CC=CC=C1OC PFYHAAAQPNMZHO-UHFFFAOYSA-N 0.000 description 2
- YGDGZDGRCWHDOU-UHFFFAOYSA-N methyl 4-[[5-chloro-4-(2-hydroxyphenyl)thiophen-2-yl]sulfonylamino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=CC(C=2C(=CC=CC=2)O)=C(Cl)S1 YGDGZDGRCWHDOU-UHFFFAOYSA-N 0.000 description 2
- NRTWXBXJSGGTTE-UHFFFAOYSA-N methyl 4-amino-2-methylbenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1C NRTWXBXJSGGTTE-UHFFFAOYSA-N 0.000 description 2
- NZYIXVITXNNBQT-UHFFFAOYSA-N methyl 5-aminopyridine-2-carboxylate;hydrochloride Chemical compound Cl.COC(=O)C1=CC=C(N)C=N1 NZYIXVITXNNBQT-UHFFFAOYSA-N 0.000 description 2
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
- 125000000962 organic group Chemical group 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 238000005897 peptide coupling reaction Methods 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- VZOPRCCTKLAGPN-ZFJVMAEJSA-L potassium;sodium;(2r,3r)-2,3-dihydroxybutanedioate;tetrahydrate Chemical compound O.O.O.O.[Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VZOPRCCTKLAGPN-ZFJVMAEJSA-L 0.000 description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 229960004034 sitagliptin Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 2
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 2
- SJMDMGHPMLKLHQ-UHFFFAOYSA-N tert-butyl 2-aminoacetate Chemical compound CC(C)(C)OC(=O)CN SJMDMGHPMLKLHQ-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000000101 thioether group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960002277 tolazamide Drugs 0.000 description 2
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 108010072897 transcription factor Brn-2 Proteins 0.000 description 2
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical class Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 1
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- KCGZGJOBKAXVSU-UHFFFAOYSA-N (4-iodophenyl)methanamine Chemical compound NCC1=CC=C(I)C=C1 KCGZGJOBKAXVSU-UHFFFAOYSA-N 0.000 description 1
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- NGJOFQZEYQGZMB-KTKZVXAJSA-N (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NGJOFQZEYQGZMB-KTKZVXAJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 description 1
- 125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- ZIKPHGJVHWZEFH-UHFFFAOYSA-N 2-(2,5-dimethoxyphenyl)acetamide Chemical compound COC1=CC=C(OC)C(CC(N)=O)=C1 ZIKPHGJVHWZEFH-UHFFFAOYSA-N 0.000 description 1
- BBZDYQUXRFATHZ-UHFFFAOYSA-N 2-(2,5-dimethoxyphenyl)acetic acid Chemical compound COC1=CC=C(OC)C(CC(O)=O)=C1 BBZDYQUXRFATHZ-UHFFFAOYSA-N 0.000 description 1
- QFBYQIUBLBNTDO-UHFFFAOYSA-N 2-(2,6-dimethoxyphenyl)acetic acid Chemical compound COC1=CC=CC(OC)=C1CC(O)=O QFBYQIUBLBNTDO-UHFFFAOYSA-N 0.000 description 1
- XCHVZBMNFXWCTR-UHFFFAOYSA-N 2-(3-methoxy-4-methylphenyl)acetic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1C XCHVZBMNFXWCTR-UHFFFAOYSA-N 0.000 description 1
- TXZVCDJZNRCDKW-UHFFFAOYSA-N 2-(4-methoxycarbonylphenyl)acetic acid Chemical compound COC(=O)C1=CC=C(CC(O)=O)C=C1 TXZVCDJZNRCDKW-UHFFFAOYSA-N 0.000 description 1
- AMSNIKBDIDNPSM-UHFFFAOYSA-N 2-[(4-cyanophenyl)methylazaniumyl]acetate Chemical compound OC(=O)CNCC1=CC=C(C#N)C=C1 AMSNIKBDIDNPSM-UHFFFAOYSA-N 0.000 description 1
- RBORKPSJXPTVGB-UHFFFAOYSA-N 2-[[4-(4-cyclohexylbenzoyl)oxyphenyl]methyl-[4-[[2-(4-methoxyphenyl)acetyl]amino]benzoyl]amino]acetic acid Chemical compound C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(=O)N(CC(O)=O)CC=2C=CC(OC(=O)C=3C=CC(=CC=3)C3CCCCC3)=CC=2)C=C1 RBORKPSJXPTVGB-UHFFFAOYSA-N 0.000 description 1
- IPNVDSNCDPKMDY-UHFFFAOYSA-N 2-[[4-(4-heptoxybenzoyl)oxy-2-methoxyphenyl]methyl-[2-methoxy-4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoyl]amino]acetic acid Chemical compound C1=CC(OCCCCCCC)=CC=C1C(=O)OC(C=C1OC)=CC=C1CN(CC(O)=O)C(=O)C(C(=C1)OC)=CC=C1NC(=O)CC1=CC=C(OC)C=C1C(F)(F)F IPNVDSNCDPKMDY-UHFFFAOYSA-N 0.000 description 1
- RARLHNWMIIHPCJ-UHFFFAOYSA-N 2-[[4-(4-heptoxybenzoyl)oxyphenyl]methyl-[2-methoxy-4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoyl]amino]acetic acid Chemical compound C1=CC(OCCCCCCC)=CC=C1C(=O)OC(C=C1)=CC=C1CN(CC(O)=O)C(=O)C(C(=C1)OC)=CC=C1NC(=O)CC1=CC=C(OC)C=C1C(F)(F)F RARLHNWMIIHPCJ-UHFFFAOYSA-N 0.000 description 1
- ARNNKMSDQGSLBR-UHFFFAOYSA-N 2-[[4-(4-heptoxybenzoyl)oxyphenyl]methyl-[4-[2-[4-methoxy-2-(trifluoromethyl)anilino]-2-oxoethyl]benzoyl]amino]acetic acid Chemical compound C1=CC(OCCCCCCC)=CC=C1C(=O)OC(C=C1)=CC=C1CN(CC(O)=O)C(=O)C(C=C1)=CC=C1CC(=O)NC1=CC=C(OC)C=C1C(F)(F)F ARNNKMSDQGSLBR-UHFFFAOYSA-N 0.000 description 1
- ISGXFMSKFDLMJY-UHFFFAOYSA-N 2-[[4-(4-hexoxybenzoyl)oxyphenyl]methyl-[4-[[2-(4-methoxyphenyl)acetyl]amino]benzoyl]amino]acetic acid Chemical compound C1=CC(OCCCCCC)=CC=C1C(=O)OC(C=C1)=CC=C1CN(CC(O)=O)C(=O)C(C=C1)=CC=C1NC(=O)CC1=CC=C(OC)C=C1 ISGXFMSKFDLMJY-UHFFFAOYSA-N 0.000 description 1
- FVYMDWKDWDCVPY-UHFFFAOYSA-N 2-[[4-(6-heptoxypyridine-3-carbonyl)oxyphenyl]methyl-[4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoyl]amino]acetic acid Chemical compound C1=NC(OCCCCCCC)=CC=C1C(=O)OC(C=C1)=CC=C1CN(CC(O)=O)C(=O)C(C=C1)=CC=C1NC(=O)CC1=CC=C(OC)C=C1C(F)(F)F FVYMDWKDWDCVPY-UHFFFAOYSA-N 0.000 description 1
- VZYRHZBUKHZBAN-UHFFFAOYSA-N 2-[[4-[4-(4-chlorophenyl)benzoyl]oxyphenyl]methyl-[4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoyl]amino]acetic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(=O)N(CC(O)=O)CC=2C=CC(OC(=O)C=3C=CC(=CC=3)C=3C=CC(Cl)=CC=3)=CC=2)C=C1 VZYRHZBUKHZBAN-UHFFFAOYSA-N 0.000 description 1
- TUKIMKYMZWWPOP-UHFFFAOYSA-N 2-[[4-[[2-(4-methoxyphenyl)acetyl]amino]benzoyl]-[[4-(4-octoxybenzoyl)oxyphenyl]methyl]amino]acetic acid Chemical compound C1=CC(OCCCCCCCC)=CC=C1C(=O)OC(C=C1)=CC=C1CN(CC(O)=O)C(=O)C(C=C1)=CC=C1NC(=O)CC1=CC=C(OC)C=C1 TUKIMKYMZWWPOP-UHFFFAOYSA-N 0.000 description 1
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- WMPTYRGXBUYONY-UHFFFAOYSA-N 2-chloroquinazoline Chemical compound C1=CC=CC2=NC(Cl)=NC=C21 WMPTYRGXBUYONY-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- HTETWBCZCBKMNJ-UHFFFAOYSA-N 2-heptoxybenzoic acid Chemical compound CCCCCCCOC1=CC=CC=C1C(O)=O HTETWBCZCBKMNJ-UHFFFAOYSA-N 0.000 description 1
- GXCHMBDPMVPLTM-UHFFFAOYSA-N 2-hydroxy-4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(O)=O)C(O)=C1 GXCHMBDPMVPLTM-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- UPGQEVTVXFIFAJ-UHFFFAOYSA-N 3-methoxy-4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]benzoic acid Chemical compound COc1ccc(CC(=O)Nc2ccc(cc2OC)C(O)=O)c(c1)C(F)(F)F UPGQEVTVXFIFAJ-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- LJANCPRIUMHGJE-UHFFFAOYSA-N 4-(2-bromoacetyl)benzonitrile Chemical compound BrCC(=O)C1=CC=C(C#N)C=C1 LJANCPRIUMHGJE-UHFFFAOYSA-N 0.000 description 1
- YNYYRDUFMDDJMV-UHFFFAOYSA-N 4-(3-methylbutoxy)benzoic acid Chemical compound CC(C)CCOC1=CC=C(C(O)=O)C=C1 YNYYRDUFMDDJMV-UHFFFAOYSA-N 0.000 description 1
- LDZXQHVHQVZPNZ-UHFFFAOYSA-N 4-(4-methylphenyl)benzoyl chloride Chemical compound C1=CC(C)=CC=C1C1=CC=C(C(Cl)=O)C=C1 LDZXQHVHQVZPNZ-UHFFFAOYSA-N 0.000 description 1
- UMLFTCYAQPPZER-UHFFFAOYSA-N 4-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=C(C#N)C=C1 UMLFTCYAQPPZER-UHFFFAOYSA-N 0.000 description 1
- IALWCYFULVHLEC-UHFFFAOYSA-N 4-(octyloxy)benzoic acid Chemical compound CCCCCCCCOC1=CC=C(C(O)=O)C=C1 IALWCYFULVHLEC-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- YMVQORPTWQKVNZ-UHFFFAOYSA-N 4-[[2-(4-methoxyphenyl)acetyl]amino]benzoic acid Chemical compound C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(O)=O)C=C1 YMVQORPTWQKVNZ-UHFFFAOYSA-N 0.000 description 1
- HLILMMHUSZGRNG-UHFFFAOYSA-N 4-[[2-[4-methoxy-2-(trifluoromethyl)phenyl]acetyl]amino]-2-propan-2-yloxybenzoic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(O)=O)C(OC(C)C)=C1 HLILMMHUSZGRNG-UHFFFAOYSA-N 0.000 description 1
- GRZWUJICCFHRDT-UHFFFAOYSA-N 4-[[4-(4-heptoxybenzoyl)oxyphenyl]methyl-(4-methoxybenzoyl)amino]butanoic acid Chemical compound C1=CC(OCCCCCCC)=CC=C1C(=O)OC(C=C1)=CC=C1CN(CCCC(O)=O)C(=O)C1=CC=C(OC)C=C1 GRZWUJICCFHRDT-UHFFFAOYSA-N 0.000 description 1
- UPCQKIXJNMOEAO-UHFFFAOYSA-N 4-[[4-(4-methylphenyl)anilino]methyl]benzaldehyde Chemical compound C1=CC(C)=CC=C1C(C=C1)=CC=C1NCC1=CC=C(C=O)C=C1 UPCQKIXJNMOEAO-UHFFFAOYSA-N 0.000 description 1
- RHNKDCWEHMNSPU-UHFFFAOYSA-N 4-[[4-(4-methylphenyl)phenoxy]methyl]benzaldehyde Chemical compound C1=CC(C)=CC=C1C(C=C1)=CC=C1OCC1=CC=C(C=O)C=C1 RHNKDCWEHMNSPU-UHFFFAOYSA-N 0.000 description 1
- ALSXQRMFYTZSMB-UHFFFAOYSA-N 4-[[4-(4-methylphenyl)phenyl]sulfonylmethyl]benzaldehyde Chemical compound C1=CC(C)=CC=C1C1=CC=C(S(=O)(=O)CC=2C=CC(C=O)=CC=2)C=C1 ALSXQRMFYTZSMB-UHFFFAOYSA-N 0.000 description 1
- FXOBABYAONFANX-UHFFFAOYSA-N 4-[[[4-methoxy-2-(trifluoromethyl)benzoyl]amino]methyl]benzoic acid Chemical compound FC(F)(F)C1=CC(OC)=CC=C1C(=O)NCC1=CC=C(C(O)=O)C=C1 FXOBABYAONFANX-UHFFFAOYSA-N 0.000 description 1
- XWQVQSXLXAXOPJ-QNGMFEMESA-N 4-[[[6-[5-chloro-2-[[4-[[(2r)-1-methoxypropan-2-yl]amino]cyclohexyl]amino]pyridin-4-yl]pyridin-2-yl]amino]methyl]oxane-4-carbonitrile Chemical compound C1CC(N[C@H](C)COC)CCC1NC1=CC(C=2N=C(NCC3(CCOCC3)C#N)C=CC=2)=C(Cl)C=N1 XWQVQSXLXAXOPJ-QNGMFEMESA-N 0.000 description 1
- TUXYZHVUPGXXQG-UHFFFAOYSA-N 4-bromobenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C=C1 TUXYZHVUPGXXQG-UHFFFAOYSA-N 0.000 description 1
- DENKGPBHLYFNGK-UHFFFAOYSA-N 4-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Br)C=C1 DENKGPBHLYFNGK-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- QCIWHVKGVVQHIY-UHFFFAOYSA-N 4-cyclohexylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1CCCCC1 QCIWHVKGVVQHIY-UHFFFAOYSA-N 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- OTHIDQZVUQAMEW-UHFFFAOYSA-N 4-heptoxybenzoyl chloride Chemical compound CCCCCCCOC1=CC=C(C(Cl)=O)C=C1 OTHIDQZVUQAMEW-UHFFFAOYSA-N 0.000 description 1
- HBQUXMZZODHFMJ-UHFFFAOYSA-N 4-hexoxybenzoic acid Chemical compound CCCCCCOC1=CC=C(C(O)=O)C=C1 HBQUXMZZODHFMJ-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- BTRQZDUCUGJMPS-UHFFFAOYSA-N 4-methoxy-2-(trifluoromethyl)aniline Chemical compound COC1=CC=C(N)C(C(F)(F)F)=C1 BTRQZDUCUGJMPS-UHFFFAOYSA-N 0.000 description 1
- REIDAMBAPLIATC-UHFFFAOYSA-M 4-methoxycarbonylbenzoate Chemical compound COC(=O)C1=CC=C(C([O-])=O)C=C1 REIDAMBAPLIATC-UHFFFAOYSA-M 0.000 description 1
- NQUVCRCCRXRJCK-UHFFFAOYSA-N 4-methylbenzoyl chloride Chemical compound CC1=CC=C(C(Cl)=O)C=C1 NQUVCRCCRXRJCK-UHFFFAOYSA-N 0.000 description 1
- BOZLUAUKDKKZHJ-UHFFFAOYSA-N 4-nonoxybenzoic acid Chemical compound CCCCCCCCCOC1=CC=C(C(O)=O)C=C1 BOZLUAUKDKKZHJ-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 1
- HSODMUBHOXGNNQ-UHFFFAOYSA-N 5-hydroxypyridine-2-carbaldehyde Chemical compound OC1=CC=C(C=O)N=C1 HSODMUBHOXGNNQ-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- LCGTWRLJTMHIQZ-UHFFFAOYSA-N 5H-dibenzo[b,f]azepine Chemical compound C1=CC2=CC=CC=C2NC2=CC=CC=C21 LCGTWRLJTMHIQZ-UHFFFAOYSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- RKGUGJAQQYOUKE-UHFFFAOYSA-N CC(C)(C)OC(=O)CNC(=O)C1=CC=C([N+]([O-])=O)C=C1 Chemical compound CC(C)(C)OC(=O)CNC(=O)C1=CC=C([N+]([O-])=O)C=C1 RKGUGJAQQYOUKE-UHFFFAOYSA-N 0.000 description 1
- WVQAOOGIAGWTKD-UHFFFAOYSA-N CC1C=CC(=CN1CC(=O)OC(C)(C)C)NC(=O)CC2=C(C=C(C=C2)OC)C(F)(F)F Chemical compound CC1C=CC(=CN1CC(=O)OC(C)(C)C)NC(=O)CC2=C(C=C(C=C2)OC)C(F)(F)F WVQAOOGIAGWTKD-UHFFFAOYSA-N 0.000 description 1
- VZDCTAXBWRWOTE-UHFFFAOYSA-N CCCCCCCOC1=CC=C(C=C1)C(=O)OC2=CC=C(C=C2)CN(CCCC)C(=O)C3=CC=C(C=C3)OC Chemical compound CCCCCCCOC1=CC=C(C=C1)C(=O)OC2=CC=C(C=C2)CN(CCCC)C(=O)C3=CC=C(C=C3)OC VZDCTAXBWRWOTE-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RAPBNVDSDCTNRC-UHFFFAOYSA-N Chlorobenzilate Chemical compound C=1C=C(Cl)C=CC=1C(O)(C(=O)OCC)C1=CC=C(Cl)C=C1 RAPBNVDSDCTNRC-UHFFFAOYSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 101100441092 Danio rerio crlf3 gene Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical group NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 229940100607 GPR119 agonist Drugs 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- OUBORTRIKPEZMG-UHFFFAOYSA-N INT-2 Chemical compound Nc1c(ncn1-c1ccc(F)cc1)C(=N)C#N OUBORTRIKPEZMG-UHFFFAOYSA-N 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000035554 Proglucagon Human genes 0.000 description 1
- 108010058003 Proglucagon Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- UVCRLTMCDUXFSL-UHFFFAOYSA-N [4-(4-methylphenyl)phenyl]boronic acid Chemical compound C1=CC(C)=CC=C1C1=CC=C(B(O)O)C=C1 UVCRLTMCDUXFSL-UHFFFAOYSA-N 0.000 description 1
- SMJGQJDIYLSFDS-UHFFFAOYSA-N [4-[[(4-aminobenzoyl)-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]methyl]phenyl] 4-heptoxybenzoate Chemical compound C1=CC(OCCCCCCC)=CC=C1C(=O)OC(C=C1)=CC=C1CN(CC(=O)OC(C)(C)C)C(=O)C1=CC=C(N)C=C1 SMJGQJDIYLSFDS-UHFFFAOYSA-N 0.000 description 1
- GRRJRPNJFJEEPK-UHFFFAOYSA-N [4-methoxy-2-(trifluoromethyl)phenyl]methanamine Chemical compound COC1=CC=C(CN)C(C(F)(F)F)=C1 GRRJRPNJFJEEPK-UHFFFAOYSA-N 0.000 description 1
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 230000008856 allosteric binding Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 150000003974 aralkylamines Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 150000001503 aryl iodides Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- MXOQNVMDKHLYCZ-UHFFFAOYSA-N benzamidoxime Chemical compound ON=C(N)C1=CC=CC=C1 MXOQNVMDKHLYCZ-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000003857 carboxamides Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical class OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 125000002676 chrysenyl group Chemical group C1(=CC=CC=2C3=CC=C4C=CC=CC4=C3C=CC12)* 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000005266 diarylamine group Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- BFXLJWUGRPGMFU-UHFFFAOYSA-N dipropoxyphosphinothioyl n,n-diethylcarbamodithioate;sulfane Chemical compound S.CCCOP(=S)(OCCC)SC(=S)N(CC)CC BFXLJWUGRPGMFU-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- ILDJJTQWIZLGPO-UHFFFAOYSA-N ethyl 6-chloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=C(Cl)N=C1 ILDJJTQWIZLGPO-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960003468 gliquidone Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 125000005252 haloacyl group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- UWNADWZGEHDQAB-UHFFFAOYSA-N i-Pr2C2H4i-Pr2 Natural products CC(C)CCC(C)C UWNADWZGEHDQAB-UHFFFAOYSA-N 0.000 description 1
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005462 imide group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000003427 indacenyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 229940090473 januvia Drugs 0.000 description 1
- 230000032297 kinesis Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- WLHQHAUOOXYABV-UHFFFAOYSA-N lornoxicam Chemical compound OC=1C=2SC(Cl)=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 WLHQHAUOOXYABV-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- PQQHWMQPDGJAGG-UHFFFAOYSA-N methyl 2-(4-heptoxyphenyl)acetate Chemical compound CCCCCCCOC1=CC=C(CC(=O)OC)C=C1 PQQHWMQPDGJAGG-UHFFFAOYSA-N 0.000 description 1
- UEPVBDQJWSGTPI-UHFFFAOYSA-N methyl 4-[2-[4-methoxy-2-(trifluoromethyl)anilino]-2-oxoethyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CC(=O)NC1=CC=C(OC)C=C1C(F)(F)F UEPVBDQJWSGTPI-UHFFFAOYSA-N 0.000 description 1
- DSHBGNPOIBSIOQ-UHFFFAOYSA-N methyl 4-amino-2-chlorobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1Cl DSHBGNPOIBSIOQ-UHFFFAOYSA-N 0.000 description 1
- BPAKMNNACPYTAY-UHFFFAOYSA-N methyl 4-amino-2-fluorobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1F BPAKMNNACPYTAY-UHFFFAOYSA-N 0.000 description 1
- WKVJBYKFGNVWLM-UHFFFAOYSA-N methyl 4-amino-3-chlorobenzoate Chemical compound COC(=O)C1=CC=C(N)C(Cl)=C1 WKVJBYKFGNVWLM-UHFFFAOYSA-N 0.000 description 1
- DOMJYWCXCVFKCA-UHFFFAOYSA-N methyl 4-amino-3-fluorobenzoate Chemical compound COC(=O)C1=CC=C(N)C(F)=C1 DOMJYWCXCVFKCA-UHFFFAOYSA-N 0.000 description 1
- OCZXDVNSNDITBS-UHFFFAOYSA-N methyl 4-amino-3-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(N)C(O)=C1 OCZXDVNSNDITBS-UHFFFAOYSA-N 0.000 description 1
- ZHIPSMIKSRYZFV-UHFFFAOYSA-N methyl 4-amino-3-methylbenzoate Chemical compound COC(=O)C1=CC=C(N)C(C)=C1 ZHIPSMIKSRYZFV-UHFFFAOYSA-N 0.000 description 1
- AQIZZMSROAYWPJ-UHFFFAOYSA-N methyl 4-amino-3-propan-2-yloxybenzoate Chemical compound COC(=O)C1=CC=C(N)C(OC(C)C)=C1 AQIZZMSROAYWPJ-UHFFFAOYSA-N 0.000 description 1
- LZXXNPOYQCLXRS-UHFFFAOYSA-N methyl 4-aminobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1 LZXXNPOYQCLXRS-UHFFFAOYSA-N 0.000 description 1
- FEIOASZZURHTHB-UHFFFAOYSA-N methyl 4-formylbenzoate Chemical compound COC(=O)C1=CC=C(C=O)C=C1 FEIOASZZURHTHB-UHFFFAOYSA-N 0.000 description 1
- JACPDLJUQLKABC-UHFFFAOYSA-N methyl 6-aminopyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(N)N=C1 JACPDLJUQLKABC-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- NKJXMLIWSJATEE-UHFFFAOYSA-N n'-hydroxy-4-methylbenzenecarboximidamide Chemical compound CC1=CC=C(C(N)=NO)C=C1 NKJXMLIWSJATEE-UHFFFAOYSA-N 0.000 description 1
- BFYLULHOYZNWPC-UHFFFAOYSA-N n-[[4,5-dimethyl-1-[(2-methylphenyl)methyl]imidazol-2-yl]methyl]-2,4-dimethoxy-n-(3-methylbutyl)benzamide Chemical compound COC1=CC(OC)=CC=C1C(=O)N(CCC(C)C)CC1=NC(C)=C(C)N1CC1=CC=CC=C1C BFYLULHOYZNWPC-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- VOVJEXLDAMDFBR-UHFFFAOYSA-N n-methyl-4-(4-methylphenyl)aniline Chemical compound C1=CC(NC)=CC=C1C1=CC=C(C)C=C1 VOVJEXLDAMDFBR-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- KKVUFSINQFSJNK-UHFFFAOYSA-N o-tert-butylhydroxylamine Chemical compound CC(C)(C)ON KKVUFSINQFSJNK-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- QQOXBFUTRLDXDP-UHFFFAOYSA-N p-Aminosalicylic acid methyl ester Chemical compound COC(=O)C1=CC=C(N)C=C1O QQOXBFUTRLDXDP-UHFFFAOYSA-N 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 210000002571 pancreatic alpha cell Anatomy 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- SEVSMVUOKAMPDO-UHFFFAOYSA-N para-Acetoxybenzaldehyde Natural products CC(=O)OC1=CC=C(C=O)C=C1 SEVSMVUOKAMPDO-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- CCSRKEPLNZYEFW-UHFFFAOYSA-N tert-butyl 2-[(4-cyanophenyl)methyl-(4-nitrobenzoyl)amino]acetate Chemical compound C=1C=C([N+]([O-])=O)C=CC=1C(=O)N(CC(=O)OC(C)(C)C)CC1=CC=C(C#N)C=C1 CCSRKEPLNZYEFW-UHFFFAOYSA-N 0.000 description 1
- WZMCOFRVMIZOLB-UHFFFAOYSA-N tert-butyl 2-[(4-cyanophenyl)methylamino]acetate Chemical compound CC(C)(C)OC(=O)CNCC1=CC=C(C#N)C=C1 WZMCOFRVMIZOLB-UHFFFAOYSA-N 0.000 description 1
- PJLNMSZKNZTZHM-UHFFFAOYSA-N tert-butyl 2-[(4-hydroxyphenyl)methyl-[4-[[2-(4-methoxyphenyl)acetyl]amino]benzoyl]amino]acetate Chemical compound C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C(=O)N(CC(=O)OC(C)(C)C)CC=2C=CC(O)=CC=2)C=C1 PJLNMSZKNZTZHM-UHFFFAOYSA-N 0.000 description 1
- OSWULUXZFOQIRU-UHFFFAOYSA-N tert-butyl 2-aminoacetate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)CN OSWULUXZFOQIRU-UHFFFAOYSA-N 0.000 description 1
- NBRKLOOSMBRFMH-UHFFFAOYSA-N tert-butyl chloride Chemical compound CC(C)(C)Cl NBRKLOOSMBRFMH-UHFFFAOYSA-N 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical class OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000004927 thianaphthalenyl group Chemical group S1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000005259 triarylamine group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- SZYJELPVAFJOGJ-UHFFFAOYSA-N trimethylamine hydrochloride Chemical compound Cl.CN(C)C SZYJELPVAFJOGJ-UHFFFAOYSA-N 0.000 description 1
- NRZWQKGABZFFKE-UHFFFAOYSA-N trimethylsulfonium Chemical compound C[S+](C)C NRZWQKGABZFFKE-UHFFFAOYSA-N 0.000 description 1
- 125000003960 triphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C3=CC=CC=C3C12)* 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 229940007428 victoza Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D309/06—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Nanotechnology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Description
本願は、2011年5月31日に出願された出願第61/491,446号、2011年9月16日に出願された出願第61/535,750号、および2011年12月12日に出願された出願第61/569,759号の優先権の利益を主張する。これらの出願は全て、明確に、その全体が参考として本明細書に援用される。
本発明は、グルカゴン様ペプチド1(GLP−1)受容体を結合する化合物、該化合物の合成方法、該化合物の治療的および/または予防的使用方法、ならびにGLP−1受容体の結晶化のためにインビトロでGLP−1受容体を安定させる上での該化合物の使用方法に関する。特に、本発明は、GLP−1受容体の調節剤である化合物、およびまたGLP−1受容体の構造分析における使用のために該受容体に及ぼす安定化効果を誘導し得る化合物に関する。本発明は、特定のクラスB GPCRの安定剤、調節剤または増強剤として作用するのに適した化合物に関する。このような化合物は、グルカゴン受容体、GIP受容体、GLP−1およびGLP−2受容体ならびにPTH受容体に対して単独で、または受容体リガンドの存在下で活性を有し得、該受容体リガンドとしては、GIP(1−42)、PTH(1−34)、グルカゴン(1−29)、GLP−2(1−33)、GLP−1(7−36)、GLP−1(9−36)、オキシントモジュリンおよびエキセンジン改変体が挙げられるが、これらに限定されない。
グルカゴン様ペプチド1受容体(GLP−1R)は、7回膜貫通型Gタンパク質共役受容体のB1ファミリーに属し、その天然のアゴニストリガンドは、ペプチドホルモンであるグルカゴン様ペプチド−1(GLP−1)である。GLP−1は、小腸の腸内分泌細胞、内分泌系の膵臓のα細胞(ランゲルハンス島)、および脳において多量に発現する、GLP−1のためのプロホルモン前駆体であるプログルカゴンからの代替的な酵素的開裂によって生じるペプチドホルモンである(非特許文献1;非特許文献2;非特許文献3)。観察されるGLP−1の初期作用は、ランゲルハンス島のインスリン産生細胞に関してであった。該細胞において、GLP−1はグルコース依存性インスリン分泌を刺激する。その後、膵β細胞の増殖の刺激およびアポトーシスの阻害を含む、GLP−1の複数の追加的な抗糖尿病誘発性作用が発見された(非特許文献4;非特許文献5;非特許文献6)。
Jは、
X1A、X1B、X2A、X2Bは各々、C、CHまたはNであるが、ただし、NであるのはX1AとX1Bのうち1個以下であり、NであるのはX2AとX2Bのうち1個以下であり;
X1C、X1D、およびX1Eは各々、CHまたはNであり;
X1Fは、OまたはSであり;
各R4は独立して、H、アルキル、アルコキシ、または1つ以上のR43 で置換されたアルキル、ハロゲン、ペルハロアルキル、ペルハロアルコキシ、−CN、−OR40もしくは−NR41R42 であり;
W1は−(CRaRb)i1−L1−(CRaRb)j1−R1またはR4であるか、あるいはW1とR4が、一体となって、W1とR4が結合している環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成する(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような複素環の任意の環原子が1つ以上の−L1−R13またはR13で任意に置換されていてもよい)か、あるいはW1が、フェニル環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成し(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような縮合複素環およびフェニル環部分の任意の環原子が1つ以上のR14で任意に置換されていてもよい);L1は、−O−、−C(O)−、−OC(O)−、−C(O)O−、−NR10−、−C(O)NR10−、−N(R10)−C(O)−、−N(R10)−(CH2)n−C(O)−、−N(R10)−C(O)−N(R10)−、−N(R10)−S(O2)−、−S(O2)−NR10−、または−N(S(O2)−(CH2)n−R1)2であり;R1は、R13、−O−(CH2)n−R13、またはR10であり;
R10、R11およびR12はそれぞれ独立して、Hまたはアルキルであり;
R13は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であるか、あるいはR13とR10が、これらが結合するN原子とともに複素環を形成しており(ここで、R13の任意の環原子が1つ以上のR14またはR15で任意に置換されていてもよい);
各R14は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシ、ペルハロアルキル、およびペルハロアルコキシ、−OR10、−(CH2)n−COOR10、−SR10、−SO−R10、−SO2R10、−(CH2)n−NR11R12、−NHCO(CH2)n−R12、−N(R11)CO(CH2)n−R12、または−NH(CH2)n−R12であり;R15は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり(ここで、R15の任意の環原子が1つ以上のR14で任意に置換されていてもよい);
各R5は独立して、H、アルキル、アルコキシ、1つ以上のR53 で置換されたアルキル、ハロゲン、ペルハロアルキル、ペルハロアルコキシ、−CN、−OR50もしくは−NR51R52 であり;
W2は−(CRaRb)i2−L2−(CRaRb)j2−R2またはR5であるか、あるいはW2およびR5が、一体となって、W2およびR5が結合している環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成する(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような複素環の任意の環原子が1つ以上の−(CRaRb)i2−L2−(CRaRb)j2−R2またはR2で任意に置換されていてもよい)か、あるいはW2が、フェニル環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成し(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような複素環またはフェニル環の任意の環原子が1つ以上のR24で任意に置換されていてもよく、このような縮合環部分の1つの環原子がL3−R25で任意に置換されている);
L2は、−O−、−C(O)−、−OC(O)−、−C(O)O−、−NR20−、−C(O)NR20−、−N(R20)−C(O)−、−N(R20)−S(O2)−、−S(O2)−NR20−、−SO2−、−O(CH2)qCO−、−CO(CH2)qO−、無、オキサゾリル、オキサジアゾリル、トリアゾリル、ピラゾリル、またはピリミジニルであり;
RaおよびRbはそれぞれ独立して、H、ヒドロキシ、メチルであるか、あるいは同じ炭素に結合するRaとRbがともに一体となって、オキソまたはシクロアルキルであり;
R2は、R26、−O−(CH2)n−R26、R23またはL4−R23であり;
L4は、−O−(CH2)n−、−C≡C−、−C(O)NR20−(CH2)n−、−N(R20)−C(O)−(CH2)n−、−N(R20)−S(O2)−、−S(O2)−NR20−、またはシクロプロピレンであり;
各R20は独立して、Hまたはアルキルであり;
R23は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であるか、あるいはR23とR20が、これらが結合するN原子とともに、任意にアリールまたはヘテロアリールと縮合した複素環を形成しており(ここで、R23の任意の環原子が1つ以上のR24で任意に置換されていてもよく、R23の1つの環原子がL3−R25で任意に置換されている);
各R24は独立して、H、ハロ、アルキル、ヒドロキシ(hydoxy)、オキソ、シアノ、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、ニトロまたはアミノ、−O−(CH2)n−R21、−(CH2)n−O−R21、−O−(CH2)n−O−R21、−(CH2)n−NR21R22、−(CH2)n−N(R21)CO(CH2)n−R21、−(CH2)n−N(R21)SO2(CH2)n−R21、−(CH2)n−SO2−N(R21)−(CH2)n−R21、−(CH2)n−CO(CH2)n−R21、−(CH2)m−COO−R21、−O−(CH2)n−COO−R21または−(CH2)m−OCO−R21から選択され;
R21およびR22はそれぞれ独立して、Hまたはアルキル、−(CH2)n−COOHであるか、あるいはこれら2つが、それらが結合する窒素原子とともに3〜7員の複素環を形成することができ;
L3は、無、−O−、−(CH2)n−O−(CH2)n−、−(CH2)n−NR20−(CH2)n−であり;
各R25は独立して、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分(moieties l)のいずれか2つの縮合二環であり(ここで、R25の任意の環原子が1つ以上のR24で任意に置換されていてもよい);
各R26は独立して、H、アルキル、アルコキシ、オキソ、ヒドロキシおよびヒドロキシ置換アルキルから選択され;
Yは、−C(O)−、−CH2−、−C(O)−CH2−、または−CH2−C(O)−であり;
Zは、−(CRaRb)n−C(O)−R3、−(CRaRb)n−R3、−R34−C(O)−R3またはHであり;
R3は、−OR30、−NR31R32または−(CO)NHSO2R30であり;各R30は独立して、Hまたはアルキルであり;R31およびR32はそれぞれ独立して、Hまたは1つ以上のR33で任意に置換されたC1−C6アルキルであるか、あるいはこれら2つが、それらが結合するN原子とともに3〜7員の複素環を形成することができ;各R33は独立して、ハロ、ヒドロキシル、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、カルボキシル、−COO−R30、または−OR30であり;R34は、シクロアルキル、ヘテロシクロアルキル、アリール、またはヘテロアリールであり(ここで、R34の任意の環原子が1つ以上のR35で任意に置換されていてもよい);各R35は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシまたはペルハロアルキルであり;
R40およびR50はそれぞれ独立して、Hまたはアルキルであり;R41およびR42はそれぞれ独立して、Hまたはアルキル、−(CH2)n−COO−R40、−C(O)−R40、アリール、ヘテロアリールであるか、あるいはこれら2つが、それらが結合するN原子とともに3〜7員の複素環を形成することができ;R51およびR52はそれぞれ独立して、Hまたはアルキル、−(CH2)n−COO−R50、−C(O)−R50、アリール、ヘテロアリールであるか、あるいはこれら2つが、それらが結合するN原子とともに3〜7員の複素環を形成することができ;各R43は独立して、H、ハロ、ヒドロキシル、−NR41R42、またはアルコキシであり;各R53は独立して、H、ハロ、ヒドロキシル、−NR51R52、またはアルコキシであり;
kは0、1、2、3または4であり;
各mは独立して、0または1であり;
各nは独立して、0、1、2、3または4であり;
各qは独立して、1または2であり;
i1、i2、j1およびj2は各々、独立して、0、1、2、3または4である)
の構造を有する化合物またはその薬学的に許容可能な異性体、同位体、鏡像体、塩、エステル、プロドラッグ、水和物もしくは溶媒和物を含む。
本発明は、例えば、以下を提供する。
(項目1)
式III
(式中、
Jは、
の構造を有し;
X1A、X1B、X2A、X2Bは各々、C、CHまたはNであるが、ただし、NであるのはX1AとX1Bのうち1個以下であり、NであるのはX2AとX2Bのうち1個以下であり;
X1C、X1D、およびX1Eは各々、C、CHまたはNであり;
X1Fは、OまたはSであり;
各R4は独立して、H、アルキル、アルコキシ、または1つ以上のR43 で置換されたアルキル、ハロゲン、ペルハロアルキル、ペルハロアルコキシ、−CN、−OR40もしくは−NR41R42 であり;
W1は−(CRaRb)i1−L1−(CRaRb)j1−R1またはR4であるか、あるいはW1とR4が、一体となって、W1とR4が結合している環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成する(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような複素環の任意の環原子が1つ以上の−L1−R13またはR13で任意に置換されていてもよい)か、あるいはW1が、フェニル環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成し(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような縮合複素環およびフェニル環部分の任意の環原子が1つ以上のR14で任意に置換されていてもよい);
L1は、−O−、−C(O)−、−OC(O)−、−C(O)O−、−NR10−、−C(O)NR10−、−N(R10)−C(O)−、−N(R10)−(CH2)n−C(O)−、−N(R10)−C(O)−N(R10)−、−N(R10)−S(O2)−、−S(O2)−NR10−、または−N(S(O2)−(CH2)n−R1)2であり;
R1は、R13、−O−(CH2)n−R13、またはR10であり;
R10、R11およびR12はそれぞれ独立して、Hまたはアルキルであり;
R13は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であるか、あるいはR13とR10が、これらが結合するN原子とともに複素環を形成しており(ここで、R13の任意の環原子が1つ以上のR14またはR15で任意に置換されていてもよい);
各R14は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシ、ペルハロアルキル、およびペルハロアルコキシ、−OR10、−(CH2)n−COOR10、−SR10、−SO−R10、−SO2R10、−(CH2)n−NR11R12、−NHCO(CH2)n−R12、−N(R11)CO(CH2)n−R12、または−NH(CH2)n−R12であり;
R15は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり(ここで、R15の任意の環原子が1つ以上のR14で任意に置換されていてもよい);
各R5は独立して、H、アルキル、アルコキシ、1つ以上のR53 で置換されたアルキル、ハロゲン、ペルハロアルキル、ペルハロアルコキシ、−CN、−OR50もしくは−NR51R52 であり;
W2は−(CRaRb)i2−L2−(CRaRb)j2−R2またはR5であるか、あるいはW2およびR5が、一体となって、W2およびR5が結合している環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成する(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような複素環の任意の環原子が1つ以上の−(CRaRb)i2−L2−(CRaRb)j2−R2またはR2で任意に置換されていてもよい)か、あるいはW2が、フェニル環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成し(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような複素環またはフェニル環の任意の環原子が1つ以上のR24で任意に置換されていてもよく、このような縮合環部分の1つの環原子がL3−R25で任意に置換されている);
L2は、−O−、−C(O)−、−OC(O)−、−C(O)O−、−NR20−、−C(O)NR20−、−N(R20)−C(O)−、−N(R20)−S(O2)−、−S(O2)−NR20−、−SO2−、−O(CH2)qCO−、−CO(CH2)qO−、無、オキサゾリル、オキサジアゾリル、トリアゾリル、ピラゾリル、またはピリミジニルであり;
RaおよびRbはそれぞれ独立して、H、ヒドロキシ、メチルであるか、あるいは同じ炭素に結合するRaとRbがともに一体となって、オキソまたはシクロアルキルであり;
R2は、R26、−O−(CH2)n−R26、R23またはL4−R23であり;
L4は、−O−(CH2)n−、−C≡C−、−C(O)NR20−(CH2)n−、−N(R20)−C(O)−(CH2)n−、−N(R20)−S(O2)−、−S(O2)−NR20−、またはシクロプロピレンであり;
各R20は独立して、Hまたはアルキルであり;
R23は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であるか、あるいはR23とR20が、これらが結合するN原子とともに、任意にアリールまたはヘテロアリールと縮合した複素環を形成しており(ここで、R23の任意の環原子が1つ以上のR24で任意に置換されていてもよく、R23の1つの環原子がL3−R25で任意に置換されている);
各R24は独立して、H、ハロ、アルキル、ヒドロキシ、オキソ、シアノ、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、ニトロまたはアミノ、−O−(CH2)n−R21、−(CH2)n−O−R21、−O−(CH2)n−O−R21、−(CH2)n−NR21R22、−(CH2)n−N(R21)CO(CH2)n−R21、−(CH2)n−N(R21)SO2(CH2)n−R21、−(CH2)n−SO2−N(R21)−(CH2)n−R21、−(CH2)n−CO(CH2)n−R21、−(CH2)m−COO−R21、−O−(CH2)n−COO−R21または−(CH2)m−OCO−R21から選択され;
R21およびR22はそれぞれ独立して、Hまたはアルキル、−(CH2)n−COOHであるか、あるいはこれら2つが、それらが結合する窒素原子とともに3〜7員の複素環を形成することができ;
L3は、無、−O−、−(CH2)n−O−(CH2)n−、−(CH2)n−NR20−(CH2)n−であり;
各R25は独立して、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり(ここで、R25の任意の環原子が1つ以上のR24で任意に置換されていてもよい);
各R26は独立して、H、アルキル、アルコキシ、オキソ、ヒドロキシおよびヒドロキシ置換アルキルから選択され;
Yは、−C(O)−、−CH2−、−C(O)−CH2−、または−CH2−C(O)−であり;
Zは、−(CRaRb)n−C(O)−R3、−(CRaRb)n−R3、−R34−C(O)−R3、またはHであり;
R3は、−OR30、−NR31R32、−NH(CRaRb)n−C(O)−R3、または−(CO)NHSO2R3であり;
各R30は独立して、Hまたはアルキルであり;
R31およびR32はそれぞれ独立して、Hまたは1つ以上のR33で任意に置換されたC1−C6アルキルであるか、あるいはこれら2つが、それらが結合するN原子とともに3〜7員の複素環を形成することができ;
各R33は独立して、ハロ、ヒドロキシル、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、カルボキシル、−COO−R30、または−OR30であり;
R34は、シクロアルキル、ヘテロシクロアルキル、アリール、またはヘテロアリールであり(ここで、R34の任意の環原子が1つ以上のR35で任意に置換されていてもよい);
各R35は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシまたはペルハロアルキルであり;
R40およびR50はそれぞれ独立して、Hまたはアルキルであり;
R41およびR42はそれぞれ独立して、Hまたはアルキル、−(CH2)n−COO−R40、−C(O)−R40、アリール、ヘテロアリールであるか、あるいはこれら2つが、それらが結合するN原子とともに3〜7員の複素環を形成することができ;
R51およびR52はそれぞれ独立して、Hまたはアルキル、−(CH2)n−COO−R50、−C(O)−R50、アリール、ヘテロアリールであるか、あるいはこれら2つが、それらが結合するN原子とともに3〜7員の複素環を形成することができ;
各R43は独立して、H、ハロ、ヒドロキシル、−NR41R42、またはアルコキシであり;
各R53は独立して、H、ハロ、ヒドロキシル、−NR51R52、またはアルコキシであり;
kは0、1、2、3または4であり;
各mは独立して、0または1であり;
各nは独立して、0、1、2、3または4であり;
各qは独立して、1または2であり;
i1、i2、j1およびj2は各々、独立して、0、1、2、3または4である)
の構造を有する化合物またはその薬学的に許容可能な異性体、同位体、鏡像体、塩、エステル、プロドラッグ、水和物もしくは溶媒和物。
(項目2)
式I
の構造を有する、項目1に記載の化合物。
(項目3)
式IV
の構造を有する、項目1に記載の化合物。
(項目4)
式V
の構造を有する、項目1に記載の化合物。
(項目5)
X1A、X1B、X2A、X2Bが各々、CまたはCHである、項目1〜4に記載の化合物。
(項目6)
X1AとX1Bのうち一方がNである、項目1および2に記載の化合物。
(項目7)
X2AとX2Bのうち一方がNである、項目1〜4および6に記載の化合物。
(項目8)
X1C、X1DおよびX1Eのうち1つがNである、項目1および3に記載の化合物。
(項目9)
X1DがNである、項目1および3に記載の化合物。
(項目10)
X1FがOである、項目1および3に記載の化合物。
(項目11)
Yが−C(O)−である、項目1〜4に記載の化合物。
(項目12)
Yが−CH2−である、項目1〜4に記載の化合物。
(項目13)
Yが−C(O)−CH2−である、項目1〜4に記載の化合物。
(項目14)
Yが−CH2−C(O)−である、項目1〜4に記載の化合物。
(項目15)
Zが−(CH2)n−R3であり、ここでZのnは0、1または2である、項目1〜14に記載の化合物。
(項目16)
ZがHである、項目1〜14に記載の化合物。
(項目17)
Zが−R34−C(O)−R3である、項目1〜14に記載の化合物。
(項目18)
Zが−(CH2)n−C(O)−R3であり、ここでZのnは0、1または2である、項目1〜14に記載の化合物。
(項目19)
R3が−OHである、項目17または18に記載の化合物。
(項目20)
kが1である、項目1〜19に記載の化合物。
(項目21)
W1が−(CRaRb)i1−L1−(CRaRb)j1−R1である、項目1〜20に記載の化合物。
(項目22)
W1が環部分:
のパラ位に結合している、項目1、2、5〜7および8〜21に記載の化合物。
(項目23)
i1が0である、項目1〜22に記載の化合物。
(項目24)
i1が1である、項目1〜22に記載の化合物。
(項目25)
i1が2である、項目1〜22に記載の化合物。
(項目26)
j1が0である、項目1〜25に記載の化合物。
(項目27)
j1が1である、項目1〜25に記載の化合物。
(項目28)
j1が2である、項目1〜25に記載の化合物。
(項目29)
L1が−NR10C(O)−である、項目1〜28に記載の化合物。
(項目30)
L1が−NR10−である、項目1〜28に記載の化合物。
(項目31)
L1が−N(R10)SO2−である、項目1〜28に記載の化合物。
(項目32)
R10が−Hである、項目29〜31に記載の化合物。
(項目33)
R1がR13である、項目1〜32に記載の化合物。
(項目34)
R1が−O−(CH2)n−R13である、項目1〜32に記載の化合物。
(項目35)
R1のnが0である、項目34に記載の化合物。
(項目36)
R1のnが1である、項目34に記載の化合物。
(項目37)
R13がフェニルである、項目33〜36に記載の化合物。
(項目38)
R13がシクロアルキルまたはヘテロシクロアルキルである、項目33〜36に記載の化合物。
(項目39)
R13が、シクロペンチル、シクロヘキシル、チアゾリル、テトラヒドロフラニル、オキサゾリル、チオフェニル、1,2,4−オキサジアゾリル、フラニル、テトラヒドロ−2H−ピラニル、またはピペリジニルである、項目38に記載の化合物。
(項目40)
R13が、非置換であるか、または1つ以上の環位において、メチル、エチル、イソプロピル、t−ブチル、−CF3、メトキシ、エトキシ、ヒドロキシル、−OCF3、ハロゲン、メチルチオ、および−SO2CH3からなる群より選択される置換基で置換されている、項目33〜39に記載の化合物。
(項目41)
R13が、メチル、メトキシ、Fまたは−CF3のうちの1つ以上で置換されている、項目40に記載の化合物。
(項目42)
R1が
である、項目33に記載の化合物。
(項目43)
RaとRbの各々がHである、項目21〜42に記載の化合物。
(項目44)
RaとRbの少なくとも一方が−CH3である、項目21〜42に記載の化合物。
(項目45)
W2が−(CRaRb)i2−L2−(CRaRb)j2−R2である、項目1〜44に記載の化合物。
(項目46)
W2が環部分:
のパラ位に結合している、項目45に記載の化合物。
(項目47)
i2が0である、項目45または46に記載の化合物。
(項目48)
i2が1である、項目45または46に記載の化合物。
(項目49)
i2が2である、項目45または46に記載の化合物。
(項目50)
j2が0である、項目45〜49に記載の化合物。
(項目51)
j2が1である、項目45〜49に記載の化合物。
(項目52)
j2が2である、項目45〜49に記載の化合物。
(項目53)
L2が、−OC(O)−、−O−、オキサゾリル、オキサジアゾリル、トリアゾリル、ピラゾリル、またはピリミジニルである、項目45〜52に記載の化合物。
(項目54)
L2がオキサジアゾリルである、項目45〜53に記載の化合物。
(項目55)
R2が、アルキル、アルコキシ、−O−(CH2)n−R21、シクロアルキル、ヘテロシクロアルキル、またはアリールで置換されたフェニルである、項目45〜54に記載の化合物。
(項目56)
R2が、−(CH2)tCH3(式中、tは0、5、6、7、8または9である)で置換されたフェニルである、項目55に記載の化合物。
(項目57)
R2が、−O(CH2)tCH3(式中、tは4、5、6、7または8である)で置換されたフェニルである、項目55に記載の化合物。
(項目58)
R2が、−O−(CH2)n−R21(式中、nは1、2または3であり、R21はイソプロピルである)で置換されたフェニルである、項目55に記載の化合物。
(項目59)
R2が、R25で置換されたフェニルであり、ここで、R25はフェニル、シクロヘキシルまたはピペリジルである項目55に記載の化合物。
(項目60)
R25がメチルで置換されている、項目59に記載の化合物。
(項目61)
前記メチルがR25のオルト位に結合している、項目60に記載の化合物。
(項目62)
RaとRbの各々がHである、項目45〜61に記載の化合物。
(項目63)
RaとRbの少なくとも一方が−CH3である、項目45〜61に記載の化合物。
(項目64)
W2とR5が、一体となって、該W2とR5が結合する環と縮合して以下の構造:
(式中、Qは−(CRaRb)i2−L2−(CRaRb)j2−R2である)
を有する二環式複素環を形成する5員または6員の複素環を構成する、項目1〜44に記載の化合物。
(項目65)
Qが−C(O)−R23またはR23である、項目64に記載の化合物。
(項目66)
R23が、1つ以上のR24で置換されたフェニルである、項目65に記載の化合物。
(項目67)
W2が、ベンゾオキサゾリル、ベンゾチアゾリル、ベンゾイミダゾリル、ベンゾ[d]イソオキサゾリル、またはベンゾ[c]イソオキサゾリルであり、ここで、このような縮合環部分の任意のフェニル環原子が1つ以上のR24で任意に置換されており、このような縮合環部分の1つのフェニル環原子がL3−R25で任意に置換されている、項目1〜44に記載の化合物。
(項目68)
式II
(式中、
R1は、R13または−O−(CH2)n−R13またはR10であり;
R10、R11およびR12はそれぞれ独立して、Hまたはアルキルであり;
R13は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であるか、あるいはR13とR10が、これらが結合するN原子とともに複素環を形成しており(ここで、R13の任意の環原子が1つ以上のR14またはR15で任意に置換されていてもよい);
各R14は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシ、ペルハロアルキル、およびペルハロアルコキシ、−OR10、−(CH2)n−COOR10、−SR10、−SO−R10、−SO2R10、−NR11R12、−NHCO(CH2)n−R12、−N(R11)CO(CH2)n−R12、または−NH(CH2)n−R12であり;
R15は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり(ここで、R15の任意の環原子が1つ以上のR14で任意に置換されていてもよい);
L2は、−O−、−C(O)−、−OC(O)−、−C(O)O−、−NR20−、−C(O)NR20−、−N(R20)−C(O)−、−N(R20)−S(O2)−、−S(O2)−NR20−、−SO2−、−O(CH2)qCO−、−CO(CH2)qO−、無、オキサゾリル、オキサジアゾリル、トリアゾリル、ピラゾリル、またはピリミジニルであり;
R2は、R26、−O−(CH2)n−R26、R23または−O−(CH2)n−R23であり;
各R20は独立して、Hまたはアルキルであり;
R23は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であるか、あるいはR23とR20が、これらが結合するN原子とともに、任意にアリールまたはヘテロアリールと縮合した複素環を形成しており(ここで、R23の任意の環原子が1つ以上のR24で任意に置換されていてもよく、R23の1つの環原子がL3−R25で任意に置換されている);
各R24は独立して、H、ハロ、アルキル、ヒドロキシ、オキソ、シアノ、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、ニトロまたはアミノ、−O−(CH2)n−R21、−(CH2)n−O−R21、−O−(CH2)n−O−R21、−(CH2)n−NR21R22、−(CH2)n−N(R21)CO(CH2)n−R21、−(CH2)n−N(R21)SO2(CH2)n−R21、−(CH2)n−SO2−N(R21)−(CH2)n−R21、−(CH2)n−CO(CH2)n−R21、−(CH2)m−COO−R21、−O−(CH2)n−COO−R21または−(CH2)m−OCO−R21から選択され;
R21およびR22はそれぞれ独立して、Hまたはアルキル、−(CH2)n−COOHであるか、あるいはこれら2つが、それらが結合する窒素原子とともに3〜7員の複素環を形成することができ;
L3は、無、−O−、−(CH2)n−O−(CH2)n−、−(CH2)n−NR20−(CH2)n−であり;
各R25は独立して、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり(ここで、R25の任意の環原子が1つ以上のR24で任意に置換されていてもよい);
各R26は独立して、H、アルキル、アルコキシ、オキソ、ヒドロキシおよびヒドロキシ置換アルキルから選択され;
Zは、−(CH2)n−C(O)−R3、−(CH2)n−R3、−R34−C(O)−R3またはHであり;
R34は、シクロアルキル、ヘテロシクロアルキル、アリール、またはヘテロアリールであり(ここで、R34の任意の環原子が1つ以上のR35で任意に置換されていてもよい);
各R35は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシまたはペルハロアルキルであり;
R3は、−OR30、または−NR31R32であり;
各R30は独立して、Hまたはアルキルであり;
R31およびR32はそれぞれ独立して、Hまたは1つ以上のR33で任意に置換されたC1−C6アルキルであるか、あるいはこれら2つが、それらが結合するN原子とともに3〜7員の複素環を形成することができ;
各R33は独立して、ハロ、ヒドロキシル、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、カルボキシル、−COO−R30、または−OR30であり;
各mは独立して、0または1であり;
各nは独立して、0、1、2、3または4であり;
各qは独立して、1または2である)
の構造を有する化合物またはその薬学的に許容可能な異性体、同位体、鏡像体、塩、エステル、プロドラッグ、水和物もしくは溶媒和物。
(項目69)
R1が、メチル、エチル、イソプロピル、t−ブチル、−CF3、メトキシ、エトキシ、ヒドロキシル、−OCF3またはハロゲン、メチルチオおよび−SO2CH3からなる群より独立して選択される1つ以上の置換基で置換されたフェニルである、項目68に記載の化合物。
(項目70)
R1が、メチル、メトキシおよび−CF3からなる群より独立して選択される1つ以上の置換基で置換されたフェニルである、項目69に記載の化合物。
(項目71)
R1が
である、項目69に記載の化合物。
(項目72)
Zが−CH2C(O)OHである、項目68〜71に記載の化合物。
(項目73)
L2が、−OC(O)−、−O−、オキサゾリル、オキサジアゾリル、トリアゾリル、ピラゾリル、またはピリミジニルである、項目68〜72に記載の化合物。
(項目74)
L2が−OC(O)−である、項目73に記載の化合物。
(項目75)
L2がオキサゾリル、オキサジアゾリル、トリアゾリル、ピラゾリル、またはピリミジニルである、項目73に記載の化合物。
(項目76)
R2が、ブチルオキシ、ペンチルオキシ、ヘキシルオキシ、ヘプチルオキシまたはオクチルオキシで置換されたフェニルである、項目68〜75に記載の化合物。
(項目77)
R2が、メチル、ペンチル、ヘキシル、ヘプチル、オクチルまたはノニルで置換されたフェニルである、項目68〜76に記載の化合物。
(項目78)
R2がビフェニルである、項目68〜75に記載の化合物。
(項目79)
前記ビフェニルの遠位環がメチルで置換されている、項目78に記載の化合物。
(項目80)
前記ビフェニルのメチル置換基が該ビフェニルの遠位フェニル環のオルト位に存在している、項目79に記載の化合物。
(項目81)
以下の化合物1〜515:
から選択される、項目1に記載の化合物またはその任意の薬学的に許容可能な塩、エステル、プロドラッグ、ホモログ、互変異性体、立体異性体、同位体もしくは水和物もしくは溶媒和物。
(項目82)
化合物1、3、4、16、17、18、32、39、40、46、192、314、347、354、355、360、361、362、363、364、405、411、441、457、458および496:
から選択される、項目74に記載の化合物またはその任意の薬学的に許容可能な塩、エステル、プロドラッグ、ホモログ、互変異性体、立体異性体、同位体もしくは水和物もしくは溶媒和物。
(項目83)
項目1〜81に記載の化合物を少なくとも1つの薬学的に許容可能な担体、希釈剤または賦形剤とともに含む薬学的組成物。
(項目84)
項目1〜81に記載の化合物と第二の薬剤とを含む薬学的組み合わせ物。
(項目85)
前記第二の薬剤が、グルカゴン受容体、GIP受容体、GLP−2受容体またはPTH受容体またはグルカゴン様ペプチド1(GLP−1)受容体のアゴニストまたは調節剤である、項目84に記載の薬学的組み合わせ物。
(項目86)
前記第二の薬剤がエクセナチド、リラグルチド、タスポグルチド、アルビグルチド、またはリキシセナチドである、項目84に記載の薬学的組み合わせ物。
(項目87)
前記第二の薬剤がDPPIV阻害剤である、項目84に記載の薬学的組み合わせ物。
(項目88)
前記第二の薬剤がスルホニル尿素である、項目84に記載の薬学的組み合わせ物。
(項目89)
前記第二の薬剤がメトホルミンである、項目84に記載の薬学的組み合わせ物。
(項目90)
前記第二の薬剤がチアゾリジンジオンである、項目84に記載の薬学的組み合わせ物。
(項目91)
薬剤の調製のための項目1〜81のいずれか一項に記載の化合物の使用方法。
(項目92)
グルカゴン様ペプチド1受容体の活性化、増強またはアゴニズムの方法であって、該受容体を有効量の項目1〜81に記載の化合物または項目83に記載の薬学的組成物または項目84〜91に記載の薬学的組み合わせ物と接触させることを含む方法。
(項目93)
グルカゴン様ペプチド1(GLP−1)受容体の活性化、増強またはアゴニズムを必要とする被験体における活性化、増強またはアゴニズムの方法であって、該被験体に、式III
(式中、
Jは、
の構造を有し;
X1A、X1B、X2A、X2Bは各々、C、CHまたはNであるが、ただし、NであるのはX1AとX1Bのうち1個以下であり、NであるのはX2AとX2Bのうち1個以下であり;
X1C、X1D、およびX1Eは各々、C、CHまたはNであり;
X1Fは、OまたはSであり;
各R4は独立して、H、アルキル、アルコキシ、または1つ以上のR43 で置換されたアルキル、ハロゲン、ペルハロアルキル、ペルハロアルコキシ、−CN、−OR40もしくは−NR41R42 であり;
W1は−(CRaRb)i1−L1−(CRaRb)j1−R1またはR4であるか、あるいはW1とR4が、一体となって、W1とR4が結合している環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成する(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような複素環の任意の環原子が1つ以上の−L1−R13またはR13で任意に置換されていてもよい)か、あるいはW1が、フェニル環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成し(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような縮合複素環およびフェニル環部分の任意の環原子が1つ以上のR14で任意に置換されていてもよい);
L1は、−O−、−C(O)−、−OC(O)−、−C(O)O−、−NR10−、−C(O)NR10−、−N(R10)−C(O)−、−N(R10)−(CH2)n−C(O)−、−N(R10)−C(O)−N(R10)−、−N(R10)−S(O2)−、−S(O2)−NR10−、または−N(S(O2)−(CH2)n−R1)2であり;
R1は、R13、−O−(CH2)n−R13、またはR10であり;
R10、R11およびR12はそれぞれ独立して、Hまたはアルキルであり;
R13は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であるか、あるいはR13とR10が、これらが結合するN原子とともに複素環を形成しており(ここで、R13の任意の環原子が1つ以上のR14またはR15で任意に置換されていてもよい);
各R14は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシ、ペルハロアルキル、およびペルハロアルコキシ、−OR10、−(CH2)n−COOR10、−SR10、−SO−R10、−SO2R10、−(CH2)n−NR11R12、−NHCO(CH2)n−R12、−N(R11)CO(CH2)n−R12、または−NH(CH2)n−R12であり;
R15は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり(ここで、R15の任意の環原子が1つ以上のR14で任意に置換されていてもよい);
各R5は独立して、H、アルキル、アルコキシ、1つ以上のR53 で置換されたアルキル、ハロゲン、ペルハロアルキル、ペルハロアルコキシ、−CN、−OR50もしくは−NR51R52 であり;
W2は−(CRaRb)i2−L2−(CRaRb)j2−R2またはR5であるか、あるいはW2およびR5が、一体となって、W2およびR5が結合している環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成する(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような複素環の任意の環原子が1つ以上の−(CRaRb)i2−L2−(CRaRb)j2−R2またはR2で任意に置換されていてもよい)か、あるいはW2が、フェニル環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成し(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような複素環またはフェニル環の任意の環原子が1つ以上のR24で任意に置換されていてもよく、このような縮合環部分の1つの環原子がL3−R25で任意に置換されている);
L2は、−O−、−C(O)−、−OC(O)−、−C(O)O−、−NR20−、−C(O)NR20−、−N(R20)−C(O)−、−N(R20)−S(O2)−、−S(O2)−NR20−、−SO2−、−O(CH2)qCO−、−CO(CH2)qO−、無、オキサゾリル、オキサジアゾリル、トリアゾリル、ピラゾリル、またはピリミジニルであり;
RaおよびRbはそれぞれ独立して、H、ヒドロキシ、メチルであるか、あるいは同じ炭素に結合するRaとRbがともに一体となって、オキソまたはシクロアルキルであり;
R2は、R26、−O−(CH2)n−R26、R23またはL4−R23であり;
L4は、−O−(CH2)n−、−C≡C−、−C(O)NR20−(CH2)n−、−N(R20)−C(O)−(CH2)n−、−N(R20)−S(O2)−、−S(O2)−NR20−、またはシクロプロピレンであり;
各R20は独立して、Hまたはアルキルであり;
R23は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であるか、あるいはR23とR20が、これらが結合するN原子とともに、任意にアリールまたはヘテロアリールと縮合した複素環を形成しており(ここで、R23の任意の環原子が1つ以上のR24で任意に置換されていてもよく、R23の1つの環原子がL3−R25で任意に置換されている);
各R24は独立して、H、ハロ、アルキル、ヒドロキシ、オキソ、シアノ、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、ニトロまたはアミノ、−O−(CH2)n−R21、−(CH2)n−O−R21、−O−(CH2)n−O−R21、−(CH2)n−NR21R22、−(CH2)n−N(R21)CO(CH2)n−R21、−(CH2)n−N(R21)SO2(CH2)n−R21、−(CH2)n−SO2−N(R21)−(CH2)n−R21、−(CH2)n−CO(CH2)n−R21、−(CH2)m−COO−R21、−O−(CH2)n−COO−R21または−(CH2)m−OCO−R21から選択され;
R21およびR22はそれぞれ独立して、Hまたはアルキル、−(CH2)n−COOHであるか、あるいはこれら2つが、それらが結合する窒素原子とともに3〜7員の複素環を形成することができ;
L3は、無、−O−、−(CH2)n−O−(CH2)n−、−(CH2)n−NR20−(CH2)n−であり;
各R25は独立して、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり(ここで、R25の任意の環原子が1つ以上のR24で任意に置換されていてもよい);
各R26は独立して、H、アルキル、アルコキシ、オキソ、ヒドロキシおよびヒドロキシ置換アルキルから選択され;
Yは、−C(O)−、−CH2−、−C(O)−CH2−、または−CH2−C(O)−であり;
Zは、−(CH2)n−C(O)−R3、−(CH2)n−R3、−R34−C(O)−R3、またはHであり;
R34は、シクロアルキル、ヘテロシクロアルキル、アリール、またはヘテロアリールであり(ここで、R34の任意の環原子が1つ以上のR35で任意に置換されていてもよい);
各R35は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシまたはペルハロアルキルであり;
R3は、−OR30、−NR31R32、−NH(CRaRb)n−C(O)−R3、または−(CO)NHSO2R3であり;
各R30は独立して、Hまたはアルキルであり;
R31およびR32はそれぞれ独立して、Hまたは1つ以上のR33で任意に置換されたC1−C6アルキルであるか、あるいはこれら2つが、それらが結合するN原子とともに3〜7員の複素環を形成することができ;
各R33は独立して、ハロ、ヒドロキシル、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、カルボキシル、−COO−R30、または−OR30であり;
R40およびR50はそれぞれ独立して、Hまたはアルキルであり;
R41およびR42はそれぞれ独立して、Hまたはアルキル、−(CH2)n−COO−R40、−C(O)−R40、アリール、ヘテロアリールであるか、あるいはこれら2つが、それらが結合するN原子とともに3〜7員の複素環を形成することができ;
R51およびR52はそれぞれ独立して、Hまたはアルキル、−(CH2)n−COO−R50、−C(O)−R50、アリール、ヘテロアリールであるか、あるいはこれら2つが、それらが結合するN原子とともに3〜7員の複素環を形成することができ;
各R43は独立して、H、ハロ、ヒドロキシル、−NR41R42、またはアルコキシであり;
各R53は独立して、H、ハロ、ヒドロキシル、−NR51R52、またはアルコキシであり;
kは0、1、2、3または4であり;
各mは独立して、0または1であり;
各nは独立して、0、1、2、3または4であり;
各qは独立して、1または2であり;
i1、i2、j1およびj2は各々、独立して、0、1、2、3または4である)
の構造を有する化合物またはその薬学的に許容可能な異性体、同位体、鏡像体、塩、エステル、プロドラッグ、水和物もしくは溶媒和物を含む薬学的組成物を投与することを含む方法。
(項目94)
前記被験体がヒトである、項目93に記載の方法。
(項目95)
グルカゴン様ペプチド1受容体の活性化、増強またはアゴニズムが医学的に指示される患者の異常状態の処置方法であって、有効量の項目1〜81に記載の化合物を該患者に、該患者に有益な効果を提供するのに十分な頻度および継続時間で投与することを含む方法。
(項目96)
前記異常状態が、1型糖尿病、2型糖尿病、妊娠糖尿病、肥満、食欲過多、満腹感不足、または代謝性障害を含む、項目95に記載の方法。
本発明のある実施態様は、式I、II、III、IVまたはV:
Jは、
X1A、X1B、X2A、X2Bは各々、C、CHまたはNであるが、ただし、NであるのはX1AとX1Bのうち1個以下であり、NであるのはX2AとX2Bのうち1個以下であり;
X1C、X1D、およびX1Eは各々、C、CHまたはNであり;
X1Fは、OまたはSであり;
各R4は独立して、H、アルキル、アルコキシ、または1つ以上のR43 で置換されたアルキル、ハロゲン、ペルハロアルキル、ペルハロアルコキシ、−CN、−OR40もしくは−NR41R42 であり;
W1は−(CRaRb)i1−L1−(CRaRb)j1−R1またはR4であるか、あるいはW1とR4が、一体となって、W1とR4が結合している環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成する(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような複素環の任意の環原子が1つ以上の−L1−R13またはR13で任意に置換されていてもよい)か、あるいはW1が、フェニル環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成し(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような縮合複素環およびフェニル環部分の任意の環原子が1つ以上のR14で任意に置換されていてもよい);L1は、−O−、−C(O)−、−OC(O)−、−C(O)O−、−NR10−、−C(O)NR10−、−N(R10)−C(O)−、−N(R10)−(CH2)n−C(O)−、−N(R10)−C(O)−N(R10)−、−N(R10)−S(O2)−、−S(O2)−NR10−、または−N(S(O2)−(CH2)n−R1)2であり;R1は、R13、−O−(CH2)n−R13、またはR10であり;
R10、R11およびR12はそれぞれ独立して、Hまたはアルキルであり;
R13は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であるか、あるいはR13とR10が、これらが結合するN原子とともに複素環を形成しており(ここで、R13の任意の環原子が1つ以上のR14またはR15で任意に置換されていてもよい);
各R14は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシ、ペルハロアルキル、およびペルハロアルコキシ、−OR10、−(CH2)n−COOR10、−SR10、−SO−R10、−SO2R10、−(CH2)n−NR11R12、−NHCO(CH2)n−R12、−N(R11)CO(CH2)n−R12、または−NH(CH2)n−R12であり;R15は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり(ここで、R15の任意の環原子が1つ以上のR14で任意に置換されていてもよい);
各R5は独立して、H、アルキル、アルコキシ、1つ以上のR53 で置換されたアルキル、ハロゲン、ペルハロアルキル、ペルハロアルコキシ、−CN、−OR50もしくは−NR51R52 であり;
W2は−(CRaRb)i2−L2−(CRaRb)j2−R2またはR5であるか、あるいはW2およびR5が、一体となって、W2およびR5が結合している環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成する(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような複素環の任意の環原子が1つ以上の−(CRaRb)i2−L2−(CRaRb)j2−R2またはR2で任意に置換されていてもよい)か、あるいはW2が、フェニル環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成し(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような複素環またはフェニル環の任意の環原子が1つ以上のR24で任意に置換されていてもよく、このような縮合環部分の1つの環原子がL3−R25で任意に置換されている);
L2は、−O−、−C(O)−、−OC(O)−、−C(O)O−、−NR20−、−C(O)NR20−、−N(R20)−C(O)−、−N(R20)−S(O2)−、−S(O2)−NR20−、−SO2−、−O(CH2)qCO−、−CO(CH2)qO−、無、オキサゾリル、オキサジアゾリル、トリアゾリル、ピラゾリル、またはピリミジニルであり;
RaおよびRbはそれぞれ独立して、H、ヒドロキシ、メチルであるか、あるいは同じ炭素に結合するRaとRbがともに一体となって、オキソまたはシクロアルキルであり;
R2は、R26、−O−(CH2)n−R26、R23またはL4−R23であり;
L4は、−O−(CH2)n−、−C≡C−、−C(O)NR20−(CH2)n−、−N(R20)−C(O)−(CH2)n−、−N(R20)−S(O2)−、−S(O2)−NR20−、またはシクロプロピレンであり;
各R20は独立して、Hまたはアルキルであり;
R23は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であるか、あるいはR23とR20が、これらが結合するN原子とともに、任意にアリールまたはヘテロアリールと縮合した複素環を形成しており(ここで、R23の任意の環原子が1つ以上のR24で任意に置換されていてもよく、R23の1つの環原子がL3−R25で任意に置換されている);
各R24は独立して、H、ハロ、アルキル、ヒドロキシ、オキソ、シアノ、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、ニトロまたはアミノ、−O−(CH2)n−R21、−(CH2)n−O−R21、−O−(CH2)n−O−R21、−(CH2)n−NR21R22、−(CH2)n−N(R21)CO(CH2)n−R21、−(CH2)n−N(R21)SO2(CH2)n−R21、−(CH2)n−SO2−N(R21)−(CH2)n−R21、−(CH2)n−CO(CH2)n−R21、−(CH2)m−COO−R21、−O−(CH2)n−COO−R21または−(CH2)m−OCO−R21から選択され;
R21およびR22はそれぞれ独立して、Hまたはアルキル、−(CH2)n−COOHであるか、あるいはこれら2つが、それらが結合する窒素原子とともに3〜7員の複素環を形成することができ;
L3は、無、−O−、−(CH2)n−O−(CH2)n−、−(CH2)n−NR20−(CH2)n−であり;
各R25は独立して、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり(ここで、R25の任意の環原子が1つ以上のR24で任意に置換されていてもよい);
各R26は独立して、H、アルキル、アルコキシ、オキソ、ヒドロキシおよびヒドロキシ置換アルキルから選択され;
Yは、−C(O)−、−CH2−、−C(O)−CH2−、または−CH2−C(O)−であり;
Zは、−(CRaRb)n−C(O)−R3、−(CRaRb)n−R3、−R34−C(O)−R3またはHであり;
R3は、−OR30、−NR31R32または−(CO)NHSO2R30であり;各R30は独立して、Hまたはアルキルであり;R31およびR32はそれぞれ独立して、Hまたは1つ以上のR33で任意に置換されたC1−C6アルキルであるか、あるいはこれら2つが、それらが結合するN原子とともに3〜7員の複素環を形成することができ;各R33は独立して、ハロ、ヒドロキシル、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、カルボキシル、−COO−R30、または−OR30であり;R34は、シクロアルキル、ヘテロシクロアルキル、アリール、またはヘテロアリールであり(ここで、R34の任意の環原子が1つ以上のR35で任意に置換されていてもよい);各R35は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシまたはペルハロアルキルであり;
R40およびR50はそれぞれ独立して、Hまたはアルキルであり;R41およびR42はそれぞれ独立して、Hまたはアルキル、−(CH2)n−COO−R40、−C(O)−R40、アリール、ヘテロアリールであるか、あるいはこれら2つが、それらが結合するN原子とともに3〜7員の複素環を形成することができ;R51およびR52はそれぞれ独立して、Hまたはアルキル、−(CH2)n−COO−R50、−C(O)−R50、アリール、ヘテロアリールであるか、あるいはこれら2つが、それらが結合するN原子とともに3〜7員の複素環を形成することができ;各R43は独立して、H、ハロ、ヒドロキシル、−NR41R42、またはアルコキシであり;各R53は独立して、H、ハロ、ヒドロキシル、−NR51R52、またはアルコキシであり;
kは0、1、2、3または4であり;
各mは独立して、0または1であり;
各nは独立して、0、1、2、3または4であり;
各qは独立して、1または2であり;
i1、i2、j1およびj2は各々、独立して、0、1、2、3または4である)
の構造を有する化合物またはその薬学的に許容可能な異性体、同位体、鏡像体、塩、エステル、プロドラッグ、水和物もしくは溶媒和物を含む。
X1A、X1B、X2A、X2Bは各々、C、CHまたはNであるが、ただし、NであるのはX1AとX1Bのうち1個以下であり、NであるのはX2AとX2Bのうち1個以下であり;
各R4は独立して、H、アルキル、アルコキシ、または1つ以上のR43 で置換されたアルキル、ハロゲン、ペルハロアルキル、ペルハロアルコキシ、−CN、−OR40もしくは−NR41R42 であり;
W1は−(CRaRb)i1−L1−(CRaRb)j1−R1またはR4であるか、あるいはW1とR4が、一体となって、W1とR4が結合している環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成する(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような複素環の任意の環原子が1つ以上の−L1−R13またはR13で任意に置換されていてもよい)か、あるいはW1が、フェニル環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成し(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような縮合複素環およびフェニル環部分の任意の環原子が1つ以上のR14で任意に置換されていてもよい);
L1は、−O−、−C(O)−、−OC(O)−、−C(O)O−、−NR10−、−C(O)NR10−、−N(R10)−C(O)−、−N(R10)−(CH2)n−C(O)−、−N(R10)−C(O)−N(R10)−、−N(R10)−S(O2)−、−S(O2)−NR10−、または−N(S(O2)−(CH2)n−R1)2であり;
R1は、R13、−O−(CH2)n−R13、またはR10であり;
R10、R11およびR12はそれぞれ独立して、Hまたはアルキルであり;
R13は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であるか、あるいはR13とR10が、これらが結合するN原子とともに複素環を形成しており(ここで、R13の任意の環原子が1つ以上のR14またはR15で任意に置換されていてもよい);
各R14は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシ、ペルハロアルキル、およびペルハロアルコキシ、−OR10、−(CH2)n−COOR10、−SR10、−SO−R10、−SO2R10、−NR11R12、−NHCO(CH2)n−R12、−N(R11)CO(CH2)n−R12、または−NH(CH2)n−R12であり;
R15は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり(ここで、R15の任意の環原子が1つ以上のR14で任意に置換されていてもよい);
各R5は独立して、H、アルキル、アルコキシ、1つ以上のR53 で置換されたアルキル、ハロゲン、ペルハロアルキル、ペルハロアルコキシ、−CN、−OR50もしくは−NR51R52 であり;
W2は−(CRaRb)i2−L2−(CRaRb)j2−R2またはR5であるか、あるいはW2およびR5が、一体となって、W2およびR5が結合している環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成する(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような複素環の任意の環原子が1つ以上の−(CRaRb)i2−L2−(CRaRb)j2−R2またはR2で任意に置換されていてもよい)か、あるいはW2が、フェニル環と縮合しており、かつ1、2または3つのヘテロ原子を有する5員または6員の複素環を構成し(ここで、このようなヘテロ原子はそれぞれ独立してO、NおよびSから選択され、このような複素環またはフェニル環の任意の環原子が1つ以上のR24で任意に置換されていてもよく、このような縮合環部分の1つの環原子がL3−R25で任意に置換されている);
L2は、−O−、−C(O)−、−OC(O)−、−C(O)O−、−NR20−、−C(O)NR20−、−N(R20)−C(O)−、−N(R20)−S(O2)−、−S(O2)−NR20−、−SO2−、−O(CH2)qCO−、−CO(CH2)qO−、無、オキサゾリル、オキサジアゾリル、トリアゾリル、ピラゾリル、またはピリミジニルであり;
RaおよびRbはそれぞれ独立して、H、ヒドロキシ、メチルであるか、あるいは同じ炭素に結合するRaとRbがともに一体となって、オキソまたはシクロアルキルであり;
R2は、R26、−O−(CH2)n−R26、R23または−O−(CH2)n−R23であり;
各R20は独立して、Hまたはアルキルであり;
R23は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であるか、あるいはR23とR20が、これらが結合するN原子とともに、任意にアリールまたはヘテロアリールと縮合した複素環を形成しており(ここで、R23の任意の環原子が1つ以上のR24で任意に置換されていてもよく、R23の1つの環原子がL3−R25で任意に置換されている);
各R24は独立して、H、ハロ、アルキル、ヒドロキシ、オキソ、シアノ、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、ニトロまたはアミノ、−O−(CH2)n−R21、−(CH2)n−O−R21、−O−(CH2)n−O−R21、−(CH2)n−NR21R22、−(CH2)n−N(R21)CO(CH2)n−R21、−(CH2)n−N(R21)SO2(CH2)n−R21、−(CH2)n−SO2−N(R21)−(CH2)n−R21、−(CH2)n−CO(CH2)n−R21、−(CH2)m−COO−R21、−O−(CH2)n−COO−R21または−(CH2)m−OCO−R21から選択され;
R21およびR22はそれぞれ独立して、Hまたはアルキル、−(CH2)n−COOHであるか、あるいはこれら2つが、それらが結合する窒素原子とともに3〜7員の複素環を形成することができ;
L3は、無、−O−、−(CH2)n−O−(CH2)n−、−(CH2)n−NR20−(CH2)n−であり;
各R25は独立して、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり(ここで、R25の任意の環原子が1つ以上のR24で任意に置換されていてもよい);
各R26は独立して、H、アルキル、アルコキシ、オキソ、ヒドロキシおよびヒドロキシ置換アルキルから選択され;
Yは、−C(O)−、−CH2−、−C(O)−CH2−、または−CH2−C(O)−であり;
Zは、−(CH2)n−C(O)−R3、−(CH2)n−R3、−R34−C(O)−R3またはHであり;
R34は、シクロアルキル、ヘテロシクロアルキル、アリール、またはヘテロアリールであり(ここで、R34の任意の環原子が1つ以上のR35で任意に置換されていてもよい);
各R35は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシまたはペルハロアルキルであり;
R3は、−OR30、または−NR31R32であり;
各R30は独立して、Hまたはアルキルであり;
R31およびR32はそれぞれ独立して、Hまたは1つ以上のR33で任意に置換されたC1−C6アルキルであるか、あるいはこれら2つが、それらが結合するN原子とともに3〜7員の複素環を形成することができ;
各R33は独立して、ハロ、ヒドロキシル、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、カルボキシル、−COO−R30、または−OR30であり;
R40およびR50はそれぞれ独立して、Hまたはアルキルであり;
R41およびR42はそれぞれ独立して、Hまたはアルキル、−(CH2)n−COO−R40、−C(O)−R40、アリール、ヘテロアリールであるか、あるいはこれら2つが、それらが結合するN原子とともに3〜7員の複素環を形成することができ;
R51およびR52はそれぞれ独立して、Hまたはアルキル、−(CH2)n−COO−R50、−C(O)−R50、アリール、ヘテロアリールであるか、あるいはこれら2つが、それらが結合するN原子とともに3〜7員の複素環を形成することができ;
各R43は独立して、H、ハロ、ヒドロキシル、−NR41R42、またはアルコキシであり;
各R53は独立して、H、ハロ、ヒドロキシル、−NR51R52、またはアルコキシであり;
kは0、1、2、3または4であり;
各mは独立して、0または1であり;
各nは独立して、0、1、2、3または4であり;
各qは独立して、1または2であり;
i1、i2、j1およびj2は各々、独立して、0、1、2、3または4である)
の構造を有する化合物またはその薬学的に許容可能な異性体、同位体、鏡像体、塩、エステル、プロドラッグ、水和物もしくは溶媒和物を含む。
R1は、R13または−O−(CH2)n−R13またはR10であり;R10、R11およびR12はそれぞれ独立して、Hまたはアルキルであり;R13は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であるか、あるいはR13とR10が、これらが結合するN原子とともに複素環を形成しており(ここで、R13の任意の環原子が1つ以上のR14またはR15で任意に置換されていてもよい);各R14は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシ、ペルハロアルキル、およびペルハロアルコキシ、−OR10、−(CH2)n−COOR10、−SR10、−SO−R10、−SO2R10、−NR11R12、−NHCO(CH2)n−R12、−N(R11)CO(CH2)n−R12、または−NH(CH2)n−R12であり;R15は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり(ここで、R15の任意の環原子が1つ以上のR14で任意に置換されていてもよい);
L2は、−O−、−C(O)−、−OC(O)−、−C(O)O−、−NR20−、−C(O)NR20−、−N(R20)−C(O)−、−N(R20)−S(O2)−、−S(O2)−NR20−、−SO2−、−O(CH2)qCO−、−CO(CH2)qO−、無、オキサゾリル、オキサジアゾリル、トリアゾリル、ピラゾリル、またはピリミジニルであり;各R20は独立して、Hまたはアルキルであり;
R2は、R26、−O−(CH2)n−R26、R23または−O−(CH2)n−R23であり;R23は、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であるか、あるいはR23とR20が、これらが結合するN原子とともに、任意にアリールまたはヘテロアリールと縮合した複素環を形成しており(ここで、R23の任意の環原子が1つ以上のR24で任意に置換されていてもよく、R23の1つの環原子がL3−R25で任意に置換されている);各R24は独立して、H、ハロ、アルキル、ヒドロキシ、オキソ、シアノ、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、ニトロまたはアミノ、−O−(CH2)n−R21、−(CH2)n−O−R21、−O−(CH2)n−O−R21、−(CH2)n−NR21R22、−(CH2)n−N(R21)CO(CH2)n−R21、−(CH2)n−N(R21)SO2(CH2)n−R21、−(CH2)n−SO2−N(R21)−(CH2)n−R21、−(CH2)n−CO(CH2)n−R21、−(CH2)m−COO−R21、−O−(CH2)n−COO−R21または−(CH2)m−OCO−R21から選択され;R21およびR22はそれぞれ独立して、Hまたはアルキル、−(CH2)n−COOHであるか、あるいはこれら2つが、それらが結合する窒素原子とともに3〜7員の複素環を形成することができ;L3は、無、−O−、−(CH2)n−O−(CH2)n−、−(CH2)n−NR20−(CH2)n−であり;各R25は独立して、シクロアルキル、ヘテロシクロアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり(ここで、R25の任意の環原子が1つ以上のR24で任意に置換されていてもよい);各R26は独立して、H、アルキル、アルコキシ、オキソ、ヒドロキシおよびヒドロキシ置換アルキルから選択され;
Zは、−(CH2)n−C(O)−R3、−(CH2)n−R3、−R34−C(O)−R3またはHであり;R34は、シクロアルキル、ヘテロシクロアルキル、アリール、またはヘテロアリールであり(ここで、R34の任意の環原子が1つ以上のR35で任意に置換されていてもよい);各R35は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシまたはペルハロアルキルであり;R3は、−OR30、または−NR31R32であり;各R30は独立して、Hまたはアルキルであり;R31およびR32はそれぞれ独立して、Hまたは1つ以上のR33で任意に置換されたC1−C6アルキルであるか、あるいはこれら2つが、それらが結合するN原子とともに3〜7員の複素環を形成することができ;各R33は独立して、ハロ、ヒドロキシル、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、カルボキシル、−COO−R30、または−OR30であり;
各mは独立して、0または1であり;各nは独立して、0、1、2、3または4であり;各qは独立して、1または2である)
の構造を有する化合物またはその薬学的に許容可能な異性体、同位体、鏡像体、塩、エステル、プロドラッグ、水和物もしくは溶媒和物を含む。あるこのような実施態様において、R1は、メチル、エチル、イソプロピル、t−ブチル、−CF3、メトキシ、エトキシ、ヒドロキシル、−OCF3またはハロゲン、メチルチオおよび−SO2CH3のうちの1つ以上で置換されたフェニルであってもよく;あるこのような実施態様において、R1は、メチル、メトキシおよび−CF3のうちの1つ以上で置換されたフェニルであってもよく;あるこのような実施態様において、R1は
(下記に説明されるような)アミド結合の周りでの制限された回転の化学特性(すなわち、いくつかの二重結合特徴をC−N結合に与える共鳴)により、回転異性体の個別の種を観察し、いくつかの状況下で、該種(例を下記に示す。)を単離することができることは理解されている。アミド窒素に関する立体バルクまたは置換基を含むある構造要素が、化合物が単一の安定した回転異性体として単離され得かつ無限に存在し得る程度まで、回転異性体の安定性を高め得ることはさらに理解される。それゆえ、本発明には、1型糖尿病、2型糖尿病、妊娠糖尿病、肥満、食欲過多、満腹感不足、および代謝性障害の処置において生物活性のある本発明の化合物のいずれかの考えられ得る安定した回転異性体が含まれる。
本発明の好ましい化合物は、化合物クラスによって決定される構造活性関連性と関連した、芳香環における置換基の特定の空間配置を有する。このような置換配置はしばしば、番号付けシステムによって示されるが、番号付けシステムはしばしば、異なる環系間で一致しない。6員芳香系において、空間配置は、下記に示されるように、共通の命名法である、1,4−置換についての「パラ」、1,3−置換についての「メタ」、および1,2−置換についての「オルト」によって明記される。
本発明のGLP−1化合物、その薬学的に許容可能な塩または加水分解可能なエステルは、哺乳類種における、より好ましくはヒトにおける本明細書で特に言及された生物学的状態または障害を処置するのに有用な薬学的組成物を提供するために、薬学的に許容可能な担体と組み合わされてもよい。これらの薬学的組成物において使用される特定の担体は、所望される投与のタイプ(例えば、静脈内、経口、局所的、坐剤、または非経口的)に応じて変更してもよい。
ある実施態様において、本発明は、高い親和性および特異性でGLP−1受容体に対してアゴニスト様式にて、または活性化因子もしくは増強剤として結合する化合物を包含する。ある実施態様において、本発明の化合物は、GLP−1受容体の正のアロステリック調節剤として作用する。
化合物を調製するための一般的な合成方法
本発明の分子についての実施態様は、当業者に公知の標準的な合成技術を使用して合成され得る。本発明の化合物は、スキーム1〜22に示される一般的な合成手順を使用して合成され得る。
1H NMR(400MHz)および13C NMR(100MHz)を重水素化クロロホルム(CDCl3)またはジメチルスルホキシド−D6(DMSO)の溶液において得た。NMRスペクトルをMestrec 5.3.0、MestReNova 6.0.3−5604、またはMestreNovaLITE 5.2.5−5780を使用して処理した。質量スペクトル(LCMS)を3つの系のうちの1つを使用して得た。第1の系:Thompson ODS−A、100A、5μ(50×4.6mm)カラムを装備したAgilent 1100/6110 HPLCシステムであり、0.1%ギ酸含有水を移動相Aとして、および0.1%ギ酸含有アセトニトリルを移動相Bとして使用。方法1:勾配は、1mL/分の流速で、2.5分間移動相Bを用いて20〜100%にし、次いで100%で2.5分間保持した。方法2:1mL/分の流速で、5%で1分間、5〜95%で9分間、次いで95%で5分間。第2の系:Agilent Zorbax Extend RRHT 1.8μm(4.6×30mm)カラムを装備したAgilent 1200 LCMSであり、0.1%ギ酸含有水を移動相Aとして、0.1%ギ酸含有アセトニトリルを移動相Bとして使用。方法3:勾配は、2.5mL/分の流速で、3.0分間移動相Bを5〜95%にし、4.5mL/分の流速で95%で0.5分間保持。方法4:2.5mL/分の流速で、5〜95%で14分間の後、4.5mL/分の流速で95%で0.5分間保持。第3の系:Agilent Zorbax Extend RRHT 1.8μm、(4.6×30mm)カラムを装備したWaters Fractionlynx LCMSシステムであり、0.1%ギ酸含有水を移動相Aとして、0.1%ギ酸含有アセトニトリルを移動相Bとして使用。第4の系:Agilent Zorbax Extend RRHT 1.8μm(4.6×30mm)を装備したAgilent 1260 LCMSであり、0.1%ギ酸含有水を移動相Aとして、0.1%ギ酸含有アセトニトリルを移動相Bとして使用。方法5:勾配は、2.5ml/分の流速で3.0分間にわたって5〜95%移動相Bであり、次いで4.5mL/分の流速で95%で0.5分間保持した。方法6:2.5ml/分の流速で14分間にわたって5〜95%、次いで4.5mL/分の流速で95%で0.5分間保持した。方法7(系1を使用):0.5分間にわたって40〜95%、次いで1mL/分の流速で95%で6分間、次いで95〜40%で0.5分間保持した。方法8(系1を使用):勾配は、2.5分間にわたって移動相Bを20〜100%にし、次いで1mL/分の流速で100%で4.5分間保持した。方法9(系4を使用):2.5mL/分の流速で14分間にわたって5〜95%、次いで4.5mL/分の流速で95%で0.5分間保持した。方法10(系4を使用):勾配は、2.5ml/分の流速で3.0分間にわたって移動相Bを5〜95%にし、次いで4.5mL/分の流速で95%で0.5分間保持した。該手順において使用されたピリジン、ジクロロメタン(DCM)、テトラヒドロフラン(THF)、およびトルエンは、Aldrich Sure−Seal瓶またはAcros AcroSeal無水溶媒由来であり、窒素(N2)下で維持した。すべての反応物を磁気撹拌した。温度は外部反応温度である。Redisep(Teledyne Isco)、Telos(Kinesis)、またはGraceResolv(Grace Davison Discovery Sciences)のいずれかのシリカゲル(SiO2)カラムを装備したCombiflash RfまたはCombiflash Companionフラッシュ精製システム(Teledyne Isco)のいずれかを使用して、クロマトグラフィーを実施した。分取HPLC精製は、2つの系のうちの1つを使用して行った。第1の系:Waters SunFire Prep C18 OBD、5μm(19×150mm)カラムを装備したVarian ProStar/PrepStarシステムであり、0.05%トリフルオロ酢酸含有水を移動相Aとして、0.05%トリフルオロ酢酸含有アセトニトリルを移動相Bとして使用。勾配は、10分間にわたって40〜95%移動相Bであり、95%で5〜10分間保持した後、18mL/分の流速で40%に2分間戻す。Varian Prostar画分回収機を使用して、254nmでのUV検出によって画分を回収し、Savant SpeedVac Plus真空ポンプまたはGenevac EZ−2を使用して蒸発させた。第2の系:Agilent Prep−C18、5μm(21.2×50mm)カラムを装備したWaters Fractionlynxシステムであり、0.1%ギ酸含有水を移動相Aとして、0.1%ギ酸含有アセトニトリルを移動相Bとして使用。勾配は、7.5分間にわたって45〜95%移動相Bであり、95%で1分間保持した後、28mL/分の流速で1.5分間にわたって45%に戻した。画分を254nmでのUV検出によって、または質量によって回収し、Genevac EZ−2を使用して蒸発させた。塩になり得る(salt−able)中心を有する化合物は、トリフルオロ酢酸(TFA)塩またはギ酸塩のいずれかであると推定された。水素化反応を、特殊化したCatCartを装備したThales Nanotechnology H−Cube反応器を使用して、または標準的な実験用技術を使用して実施した。以下の略語を使用する:酢酸エチル(EA)、トリエチルアミン(TEA)、N−ヒドロキシベンゾトリアゾール(HOBt)、1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミドヒドロクロリド(EDC)、N,N−ジメチルホルムアミド(DMF)、ジメチルアセトアミド(DMA)、二炭酸ジ−tert−ブチル(Boc2O)、N,N−ジイソプロピルエチルアミン(DIEA)、酢酸(AcOH)、塩酸(HCl)、O−(7−アザベンゾトリアゾール−1−イル)−N,N,N’,N’−テトラメチルウロニウムヘキサフルオロホスフェート(HATU)、4−ジメチルアミノピリジン(DMAP)、tert−ブタノール(t−BuOH)、水素化ナトリウム(NaH)、トリアセトキシ水素化ホウ素ナトリウム、ナトリウムトリアセトキシボロヒドリド[Na(OAc)3BH]。
N−(4−ヒドロキシベンジル)−4−ニトロベンズアミド(INT−1)
DCM中の適切な酸(1〜1.2当量)およびDMAP(0.1当量)の撹拌溶液にDCC(1.3〜1.5当量)を添加した。10分後、フェノール(1当量)を添加し、反応混合物を室温で4時間まで撹拌した。粗反応混合物をDCMで希釈し、NaHCO3で洗浄した。有機層をMgSO4で乾燥させ、濃縮した。最終生成物をクロマトグラフィーまたは分取HPLCによって精製した。あるいは、最終生成物を粗反応混合物から直接精製してもよい。
DCM中のフェノール(1.0〜1.1当量)の撹拌溶液に、0℃または室温で、TEA(1.5〜4.0当量)を添加した後、酸塩化物(1.0〜2.4当量)を添加した。反応混合物は0℃で30分間撹拌され得、DMAPが任意選択的に添加され得(0.25当量)、次いで室温で18時間まで撹拌され得る。あるいは、反応混合物は、室温で18時間まで撹拌または超音波処理され得る。反応物をNaHCO3でクエンチし、水層をDCMで抽出した。有機層をMgSO4で乾燥させ、濃縮した。最終生成物をクロマトグラフィーまたは分取HPLCによって精製した。あるいは、最終生成物を粗反応混合物から直接精製してもよい。または、粗反応混合物を精製せずに次の工程において使用してもよい。
DCM中のアルデヒド(1当量)の撹拌溶液にアミノアセテート(1.0〜1.1当量)を添加した。室温で1時間撹拌した後、トリアセトキシ水素化ホウ素ナトリウム(2当量)を添加し、反応物を一晩撹拌した。粗反応混合物をNaHCO3でクエンチし、5分間撹拌した。水層をDCMで抽出し、有機層をMgSO4で乾燥させ、濃縮した。生成物をクロマトグラフィーによって単離した。
DMF中の適切なアミンまたはアミド(1当量)の撹拌溶液に、水素化ナトリウム(1.1〜2.2当量)またはTEA(2当量)またはDIEA(2当量)を添加した。室温で5分間撹拌した後、ブロモアセテート(1.0〜2.3当量)を添加し、混合物を18時間まで撹拌した。粗反応混合物をEAで希釈し、ブラインで洗浄した。有機層をMgSO4で乾燥させ、濃縮し、最終生成物をクロマトグラフィーによって単離した。
N2をパージした、THF中のアリールニトロ(1当量)の撹拌溶液にパラジウム担持炭素を添加した。反応混合物を室温または40℃で4時間までH2雰囲気に供した。反応混合物はセライトパッドで濾過され得、溶媒は濃縮され得る。粗製物質は、さらに精製せずに持ち越してもよく、クロマトグラフィーまたは分取HPLCによって精製してもよい。あるいは、THFおよび水(3:1)中のアリールニトロ(1当量)の撹拌溶液に亜ジチオン酸ナトリウム(3当量)を添加した。反応混合物を65℃に3時間まで加熱した。粗反応混合物をEAで希釈し、ブラインで洗浄した。有機層をMgSO4で乾燥させ、濃縮し、最終生成物をクロマトグラフィーによって単離した。
DMF中の適切な酸(1〜1.5当量)、アミン(1当量)およびTEA(1〜3当量)の撹拌溶液にHATU(1〜1.2当量)を添加した。反応混合物を18時間まで撹拌した。または、DMF中の適切な酸(1〜1.5当量)の撹拌溶液にHOBT(1.5当量)およびEDC(1.5当量)を添加した。2時間まで撹拌した後、DMF中のアミン(1当量)およびTEAまたはDIEA(0〜2当量)を添加し、反応混合物を室温で18時間撹拌した。
DCM中のアミン(1当量)の撹拌溶液に、0℃または室温で、酸塩化物(1.0〜2.8当量)およびTEAまたはDIPEA(1.5〜5.0当量)を添加した。反応混合物を室温で18時間まで撹拌した。反応混合物をNaHCO3で希釈した。水層をDCMで抽出し、有機層をMgSO4で乾燥させた。溶媒を濃縮し、最終生成物をクロマトグラフィーまたは分取HPLCによって精製した。あるいは、最終生成物を粗反応混合物から直接精製してもよく、粗反応混合物を精製せずに次の工程において使用してもよい。
DCM中のtert−ブトキシアミン(1当量)の撹拌溶液に、過剰のTFA(50〜110当量)または過剰の塩酸(4M、5〜10当量)を添加した。反応混合物を室温または30℃で18時間まで撹拌した。最終生成物をクロマトグラフィーまたは分取HPLCによって精製した。あるいは、反応混合物を濃縮し、さらに精製せずに持ち越してもよい。
THFまたはジオキサンおよびMeOH中のエステル(1当量)の撹拌溶液に、NaOHまたはLiOH(1.0〜2.0当量)を添加した。反応混合物を室温または60℃で18時間まで撹拌した。反応混合物をAcOHまたはHClで中和し、水で希釈するか、または濃縮するかのいずれかをした。反応混合物を水で希釈した場合、HClを添加し、反応混合物を酸性化してpH約2にした。生じた析出物を濾過によって単離し、生成物を得た。これを、クロマトグラフィー、分取HPLCによって精製してもよく、精製せずに持ち越してもよい。反応混合物を濃縮した場合、粗製物質をDCMまたはEAで希釈し、ブラインで洗浄した。有機層を濃縮し、クロマトグラフィーまたは分取HPLCによって精製し、最終生成物を得た。あるいは、粗製物質を精製せずに持ち越してもよい。
DCMまたはTHF中のアミン(1当量)の撹拌溶液に、TEAまたはカリウムtert−ブトキシド(1.5〜3当量)および適切な塩化スルホニル(1.2〜2.5当量)を添加した。反応混合物を室温または50℃で18時間まで撹拌し、次いで濃縮した。最終生成物をクロマトグラフィーまたは分取HPLCによって精製した。あるいは、粗反応混合物をさらに精製せずに持ち越してもよい。
DCM中のカルバメート(1当量)の撹拌溶液に過剰のTFA(6〜50当量)を添加した。反応混合物を室温で2時間まで撹拌した。反応混合物を濃縮し、粗生成物をさらに精製せずに使用した。
DCMまたはMTBEまたはTHF中のアルデヒドまたはケトン(0.9〜1当量)の撹拌溶液にアミン(0.9〜1.1当量)を添加した。室温で18時間まで撹拌した後、1滴の酢酸(任意)を添加し、その後、トリアセトキシ水素化ホウ素ナトリウムまたは水素化ホウ素ナトリウムまたはテトラメチルアンモニウムトリアセトキシヒドロボレート(1〜2当量)を添加した。反応混合物を18時間まで撹拌した。場合によっては、反応混合物を濾過し、適切な溶媒(DCMまたは1:1のTHF/MeOHなど)に再度溶解させ、トリアセトキシ水素化ホウ素ナトリウムまたは水素化ホウ素ナトリウムまたはテトラメチルアンモニウムトリアセトキシヒドロボレート(1〜2当量)を添加し、次いで18時間まで撹拌することが必要である。粗反応混合物をNaHCO3でクエンチし、5分間撹拌した。水層をDCMまたはEAで抽出し、有機層をMgSO4で乾燥させ、濃縮した。最終生成物をクロマトグラフィーまたは分取HPLCによって単離した。
DMFまたはTHFまたはアセトニトリル中のハロゲン化物またはメシレート(1.0〜1.5当量)の撹拌溶液に、0℃または室温で、アミンまたはアルコールまたは酸(1当量)およびK2CO3またはTEAまたはDIEA(1〜5当量)を添加した。反応混合物を室温または60℃で18時間まで撹拌した。反応混合物をNaHCO3またはブラインでクエンチし、水層をEAまたはDCMで抽出し、有機層をMgSO4で乾燥させた。あるいは、反応混合物をEAまたはDCMで希釈し、水で洗浄し、有機層をMgSO4で乾燥させた。溶媒を濃縮し、最終生成物をクロマトグラフィーまたは分取HPLCによって精製した。あるいは、最終生成物を粗反応混合物から直接精製してもよく、粗反応混合物を精製せずに次の工程において使用してもよい。
DCMまたはアセトニトリル中のクロロギ酸ニトロフェニル(1.1当量)の撹拌溶液に、0℃で、DCMまたはアセトニトリル中の適切なアルコールまたはフェノール(1当量)を添加した後、ピリジンまたはK2CO3(2当量)を添加した。90分後、反応混合物を濃縮し、クロマトグラフィーによって精製し、該アルコールまたはフェノールの活性化されたニトロフェニルカルバメートを得た。あるいは、反応混合物を濾過し、濾液を濃縮し、該アルコールまたはフェノールの活性化されたニトロフェニルカルバメートを得てもよい。得られたニトロフェニルカルバメート(1当量)をDCMおよびピリジン(2.0当量)に溶解させ、次いで、アミン(1当量)のDCM溶液に滴下した。触媒量のDMAPを添加した。反応混合物を室温または50℃で18時間まで撹拌した。粗反応混合物をDCMで希釈し、NaHCO3で洗浄し、有機層をMgSO4で乾燥させた。溶媒を濃縮し、最終生成物をクロマトグラフィーまたは分取HPLCによって精製した。あるいは、粗反応混合物を濃縮し、精製せずに次の工程において使用してもよい。
DCM中のクロロギ酸ニトロフェニル(1.1当量)の撹拌溶液に、0℃で、適切なアミン(1当量)およびDIEA(2当量)のTHF溶液を添加(滴下)した。90分後、別の適切なアミン(1当量)およびDIEA(2当量)のDCM溶液を反応混合物に添加した。触媒量のDMAPを添加した。40時間後、混合物を濃縮し、分取HPLCによって精製した。
アセトニトリルと水(10:1)またはTHF、アセトニトリルおよび水(2:2:1)中の臭化アリールまたは塩化アリールまたはヨウ化アリール(1当量)の撹拌溶液に、Na2CO3(1〜2当量)および適切なボロン酸(1.2〜1.5当量)を添加した。反応混合物をN2で10分間脱気し、次いで、適当なパラジウム触媒(例えば、PdCl2(dppf)またはPd(Ph3)4など)(0.05当量)を添加した。反応混合物をN2で5分間脱気し、次いで、マイクロ波反応器内で100〜110℃にて1時間まで加熱した。粗反応混合物をNaHCO3でクエンチした。水層をDCMで抽出し、有機層をMgSO4で乾燥させた。溶媒を濃縮し、最終生成物をクロマトグラフィーまたは分取HPLCによって精製した。あるいは、粗反応混合物をDCMで希釈し、相分離カートリッジに通し、次いで濃縮し、さらに精製せずに次の工程において使用してもよい。
DCM中のアニリンまたはフェノール(1当量)および酢酸銅(1当量)の撹拌溶液に、適切なボロン酸(1.3〜2当量)を添加した後、ピリジン(3〜5当量)および分子ふるいを添加した。反応バイアルを乾燥空気下で密封し、室温で16時間まで撹拌した。粗反応混合物をDCMで希釈し、次いでセライトパッドに通して濾過した。濾液をNaHCO3で洗浄した。有機層をMgSO4で乾燥させ、次いで濃縮し、粗生成物を得、これをさらに精製せずに次の工程において使用した。
DCMおよび任意選択により水の中のアルコール(1当量)にデス・マーチンペルヨージナン(1当量)を添加した。反応混合物を室温で18時間まで撹拌した。粗反応混合物をNaHCO3でクエンチした。水層をDCMで抽出し、合わせた有機層をMgSO4で乾燥させた。溶媒を濃縮し、最終生成物をさらに精製せずに次の工程において使用した。あるいは、クロロホルムまたはDCM中のアルコール(1当量)に酸化マンガン(IV)(10当量)を添加した。反応混合物を室温で5時間まで撹拌し、次いでセライトに通して濾過し、濃縮し、クロマトグラフィーによって精製した。
EtOH中のニトリル(1当量)の撹拌溶液に、ヒドロキシルアミン(H2O中の50%溶液、5当量)およびTEA(1.1当量)を添加した。混合物を80℃で一晩加熱し、次いで濃縮した。得られた固形物をEAに溶解させ、水で洗浄し、次いで乾燥させ(Na2SO4)、濃縮し、さらに精製せずに使用した。あるいは、DMFまたはEtOH中のニトリル(1当量)およびTEA(2〜3当量)の撹拌溶液に、ヒドロキシルアミン塩酸塩(2〜3当量)を添加した。混合物を室温から80℃までの温度で24時間まで撹拌し、次いで濃縮した。得られた固形物をEAに溶解させ、水またはブラインで洗浄し、次いで乾燥させ(Na2SO4)、濃縮し、さらに精製せずに使用した。
酸(1当量)のDMF溶液にHOBt(2当量)およびEDC(2当量)を添加した。2時間撹拌した後、アミドキシム(2当量)を添加し、混合物を室温で12時間まで撹拌した。次いで、反応混合物を100℃に12時間まで加熱した。あるいは、室温で撹拌した後、反応混合物をDCMで希釈し、NaHCO3で洗浄し、次いで乾燥させ(Na2SO4)、濃縮した。得られた残渣をEtOHに溶解させ、マイクロ波装置中で110℃にて35分間加熱した。溶媒を除去し、最終生成物を分取HPLCによって精製した。酸塩化物によってオキサジアゾールを合成するために、ジオキサンおよびDIEA(1.5当量)を、アミドキシム(1当量)の撹拌溶液に添加した後、酸塩化物(1.1当量)を添加した。反応混合物を室温で30分間、次いで120℃で6時間まで撹拌した。反応混合物を室温まで放冷し、EAで希釈し、ブラインで洗浄した。有機物を濃縮し、残渣をクロマトグラフィーによって精製した。
DMF中のギ酸リチウム(3当量)の撹拌懸濁液にDIEA(2当量)および無水酢酸(2当量)を室温で添加した。0.5〜2時間後、反応混合物にN2ガスをパージし、次いで、臭化アリールまたはヨウ化アリール(1当量)およびPdCl2(dppf)(0.1当量)のDMF溶液を添加した。反応混合物を120℃で5時間まで加熱し、次いで1Mクエン酸に注入し、EAで抽出した。有機物をブラインで洗浄し、次いで濃縮し、クロマトグラフィーによって精製した。
GLP−1 PAMシフトcAMPアッセイ:固定された化合物濃度の存在下でのペプチドリガンドの用量応答
GLP−1Rを発現するCRE−bla CHO−K1細胞系をInvitrogenから購入した。細胞を384ウェル白色平底プレートへと5000細胞/ウェル/20μL増殖培地(DMEM−高濃度グルコース、10%透析済みFBS、0.1mM NEAA、25mM Hepes、100U/mLペニシリン/100μg/mLストレプトマイシン、5μg/mLブラスチシジン、600μg/mLハイグロマイシン)で播種し、5%CO2において37℃で18時間インキュベートした。増殖培地を12μLのアッセイ緩衝液(ハンクス平衡塩溶液、10mM Hepes、0.1%BSA、pH7.4)と交換した。5×ペプチド用量応答曲線(12点)を、1.5mM IBMX、12.5%DMSO、および50μM化合物を含むアッセイ緩衝液で作成した。ペプチドリガンドはGLP−1(9−36)またはRP−101868のいずれかとした。5×ペプチド用量応答+化合物ミックスを添加し(3μL)、細胞を37℃で30分間インキュベートした。cAMPの直接的な検出を、製造元の説明書に従ってDiscoveRx HitHunter cAMPキットを使用して実施し、発光をSpectraMax M5プレート読み取り装置を使用して読み取った。発光を非線形回帰によって分析し、EC50およびEmaxを求めた。GLP−1(7−36)用量応答を含めて最大有効性を求めた。
GLP−1R CRE−bla CHO−K1細胞を384ウェル白色平底プレートに、10,000細胞/ウェル/20μL増殖培地(DMEM−高濃度グルコース、10%透析済みFBS、0.1mM NEAA、25mM Hepes、100U/mLペニシリン/100μg/mLストレプトマイシン、5μg/mLブラスチシジン、600μg/mLハイグロマイシン)で播種し、5%CO2において37℃で18時間インキュベートした。増殖培地を12μLのアッセイ緩衝液(ハンクス平衡塩溶液、10mM Hepes、0.1%BSA、pH7.4)と交換した。5×化合物用量応答曲線(12点)を、1.5mM IBMX、12.5%DMSOを含むアッセイ緩衝液で、作成した。GLP−1(9−36)を、1.5mM IBMXおよび12.5%DMSOを含むアッセイ緩衝液中で4.2μMに希釈した。5×化合物用量応答を添加した(3μL)後、0.5μLのGLP−1(9−36)を添加し、細胞を37℃で30分間インキュベートした。cAMPの直接的な検出を、製造元の説明書に従ってDiscoveRx HitHunter cAMPキットを使用して実施し、発光をSpectraMax M5プレート読み取り装置を使用して読み取った。発光を、cAMP標準曲線を使用して総cAMPへと変換し、データを非線形回帰によって分析し、EC50およびEmaxを求めた。
GLP−1(7−36):HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR−NH2(配列番号1)
GLP−1(9−36):EGTFTSDVSSYLEGQAAKEFIAWLVKGR−NH2(配列番号2)
RP−101868:GEGTFTS−Nle−LSKQMEEEAVRLFIEWLKNGR−NH2(配列番号3)
GLP−1(7−36)をGenScriptから購入した。
選択されたGLP−1調節剤についての活性データを表2に表示する。GLP−1(9−36)PAM活性範囲を以下の通り示す。+は10nM未満の活性を示し、++は10〜100nMの間の活性を示し、+++は100〜1000nMの間の活性を示し、++++は1000nM超の活性を示す。N/Aは入手不可を示す。EC20GLP−1(9−36)PAM活性範囲を以下の通り示す。+は1μM未満の活性を示し、++は1〜5μMの間の活性を示し、+++は5〜10μMの間の活性を示し、++++は10μM超の活性を示す。N/Aは入手不可を示す。
選択されたGLP−1調節剤についての活性データを表3に表示する。GLP−1(RP−101868)PAM活性範囲を以下の通り示す。+は10nM未満の活性を示し、++は10〜100nMの間の活性を示し、+++は100〜1000nMの間の活性を示し、++++は1000nM超の活性を示す。N/Aは入手不可を示す。
薬物動態試験はすべて、空腹状態の雌Sprague−Dawelyラット(Simonsen LaboratoriesまたはHarlan Laboratories)で行った。ラットはALAAC認定施設内に収容し、本研究は、施設内動物実験委員会(Institutional Animal Care and Use Committee)(IACUC)によって承認されたものであった。動物は、実験開始前に少なくとも48時間、実験室に馴化させた。
(経口AUC×IV用量)/(IV AUC×経口用量)×100。
Claims (13)
- 式I
X1A、X1B、X2A およびX2Bは各々、CHであり;
R 4は、H、アルキル、1つ以上のR43 で置換されたアルキル、ハロゲン、ペルハロアルキル、ペルハロアルコキシ、−CN、−OR40 または−NR41R42であり;
W1は−L 1 −CH 2 −R 1 であり;
L1は、−NH−C(O)−であり;
R1は、R13 であり;
R10、R11およびR12はそれぞれ独立して、Hまたはアルキルであり;
R13は、フェニルであり(ここで、R13の任意の環原子が1つ以上のR14またはR15で任意に置換されていてもよい);
各R14は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、−OR10、−(CH2)n−COOR10、−SR10、−SO−R10、−SO2R10、−(CH2)n−NR11R12、−NHCO(CH2)n−R12、−N(R11)CO(CH2)n−R12、または−NH(CH2)n−R12であり;
各R15は、シクロアルキル、ヘテロシクリルアルキル、アリール、ヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり(ここで、R15の任意の環原子が1つ以上のR14で任意に置換されていてもよい);
R 5は独立して、H、アルキル、1つ以上のR53 で置換されたアルキル、ハロゲン、ペルハロアルキル、ペルハロアルコキシ、−CN、−OR50もしくは−NR51R52 であり;
W2は−L 2 −R 2 であり;
L2は、1,2,4−オキサジアゾール−3−イルであり;
RaおよびRbはそれぞれ独立して、H、ヒドロキシ、メチルであるか、あるいは同じ炭素に結合するRaとRbがともに一体となって、オキソまたはシクロアルキルであり;
R2は、R26、−O−(CH2)n−R26、R23または−L 4−R23であり;
L4は、−O−(CH2)n−、−C≡C−、−C(O)NR20−(CH2)n−、−N(R20)−C(O)−(CH2)n−、−N(R20)−S(O2)−、−S(O2)−NR20−、またはシクロプロピレンであり;
各R20は独立して、Hまたはアルキルであり;
R23は、シクロアルキル、ヘテロシクリルアルキル、アリール、ヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であるか、あるいはR23とR20が、これらが結合するN原子とともに、任意にアリールまたはヘテロアリールと縮合した複素環を形成しており(ここで、R23の任意の環原子が1つ以上のR24で任意に置換されていてもよく、R23の1つの環原子が−L 3−R25で任意に置換されている);
各R24は独立して、H、ハロ、アルキル、ヒドロキシ、オキソ、シアノ、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、ニトロまたはアミノ、−O−(CH2)n−R21、−(CH2)n−O−R21、−O−(CH2)n−O−R21、−(CH2)n−NR21R22、−(CH2)n−N(R21)CO(CH2)n−R21、−(CH2)n−N(R21)SO2(CH2)n−R21、−(CH2)n−SO2−N(R21)−(CH2)n−R21、−(CH2)n−CO(CH2)n−R21、−(CH2)m−COO−R21、−O−(CH2)n−COO−R21または−(CH2)m−OCO−R21 であり;
R21およびR22はそれぞれ独立して、H、アルキル、または−(CH2)n−COOHであるか、あるいはR 21 およびR 22 が、それらが結合する窒素原子とともに3〜7員の複素環を形成し;
L3は、無、−O−、−(CH2)n−O−(CH2)n−、または−(CH2)n−NR20−(CH2)n−であり;
各R25は独立して、シクロアルキル、ヘテロシクリルアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり(ここで、R25の任意の環原子が1つ以上のR24で任意に置換されていてもよい);
R 26は、H、アルキル、アルコキシ、オキソ、ヒドロキシまたはヒドロキシ置換アルキルであり;
Yは、−C(O)−、−CH2−、−C(O)−CH2−、または−CH2−C(O)−であり;
Zは、−(CRaRb)n−C(O)−R3、−(CRaRb)n−R3、−R34−C(O)−R3、またはHであり;
R3は、−OR30、−NR31R32 、または−(CO)NHSO2R30 であり;
各R30は独立して、Hまたはアルキルであり;
R31およびR32はそれぞれ独立して、Hまたは1つ以上のR33で任意に置換されたC1−C6アルキルであるか、あるいはR 31 およびR 32 が、それらが結合するN原子とともに3〜7員の複素環を形成し;
各R33は独立して、ハロ、ヒドロキシル、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、カルボキシル、−COO−R30、または−OR30であり;
R34は、シクロアルキル、ヘテロシクリルアルキル、アリール、またはヘテロアリールであり(ここで、R34の任意の環原子が1つ以上のR35で任意に置換されていてもよい);
各R35は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシまたはペルハロアルキルであり;
R40およびR50はそれぞれ独立して、Hまたはアルキルであり;
R41およびR42はそれぞれ独立して、H、アルキル、−(CH2)n−COO−R40、−C(O)−R40、アリール、またはヘテロアリールであるか、あるいはR 41 およびR 42 が、それらが結合するN原子とともに3〜7員の複素環を形成し;
R51およびR52はそれぞれ独立して、Hまたはアルキル、−(CH2)n−COO−R50、−C(O)−R50、アリール、ヘテロアリールであるか、あるいはR 51 およびR 52 が、それらが結合するN原子とともに3〜7員の複素環を形成し;
各R43は独立して、H、ハロ、ヒドロキシル、−NR41R42、またはアルコキシであり;
各R53は独立して、H、ハロ、ヒドロキシル、−NR51R52、またはアルコキシであり;
kは1、2、3または4であり;
各mは独立して、0または1であり;
各nは独立して、0、1、2、3または4である)
の構造を有する化合物またはその薬学的に許容可能な塩。 - 式II
(式中、
R1は、R13 であり;
R10、R11およびR12はそれぞれ独立して、Hまたはアルキルであり;
R13は、フェニルであり(ここで、R13の任意の環原子が1つ以上のR14またはR15で任意に置換されていてもよい);
各R14は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、−OR10、−(CH2)n−COOR10、−SR10、−SO−R10、−SO2R10、−NR11R12、−NHCO(CH2)n−R12、−N(R11)CO(CH2)n−R12、または−NH(CH2)n−R12であり;
各R15は、シクロアルキル、ヘテロシクリルアルキル、アリール、ヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり(ここで、R15の任意の環原子が1つ以上のR14で任意に置換されていてもよい);
L2は、1,2,4−オキサジアゾール−3−イルであり;
R2は、R26、−O−(CH2)n−R26、R23または−O−(CH2)n−R23であり;
各R20は独立して、Hまたはアルキルであり;
R23は、シクロアルキル、ヘテロシクリルアルキル、アリール、ヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり;
各R24は独立して、H、ハロ、アルキル、ヒドロキシ、オキソ、シアノ、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、ニトロまたはアミノ、−O−(CH2)n−R21、−(CH2)n−O−R21、−O−(CH2)n−O−R21、−(CH2)n−NR21R22、−(CH2)n−N(R21)CO(CH2)n−R21、−(CH2)n−N(R21)SO2(CH2)n−R21、−(CH2)n−SO2−N(R21)−(CH2)n−R21、−(CH2)n−CO(CH2)n−R21、−(CH2)m−COO−R21、−O−(CH2)n−COO−R21または−(CH2)m−OCO−R21 であり;
R21およびR22はそれぞれ独立して、H、アルキル、−(CH2)n−COOHであるか、あるいはR 21 およびR 22 が、それらが結合する窒素原子とともに3〜7員の複素環を形成し;
L3は、無、−O−、−(CH2)n−O−(CH2)n−、または−(CH2)n−NR20−(CH2)n−であり;
各R25は独立して、シクロアルキル、ヘテロシクリルアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり(ここで、R25の任意の環原子が1つ以上のR24で任意に置換されていてもよい);
各R26は独立して、H、アルキル、アルコキシ、オキソ、ヒドロキシまたはヒドロキシ置換アルキルであり;
Zは、−(CH2)n−C(O)−R3、−(CH2)n−R3、−R34−C(O)−R3またはHであり;
R34は、シクロアルキル、ヘテロシクリルアルキル、アリール、またはヘテロアリールであり(ここで、R34の任意の環原子が1つ以上のR35で任意に置換されていてもよい);
各R35は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシまたはペルハロアルキルであり;
R3は、−OR30、または−NR31R32であり;
各R30は独立して、Hまたはアルキルであり;
R31およびR32はそれぞれ独立して、Hまたは1つ以上のR33で任意に置換されたC1−C6アルキルであるか、あるいはR 31 およびR 32 が、それらが結合するN原子とともに3〜7員の複素環を形成し;
各R33は独立して、ハロ、ヒドロキシル、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、カルボキシル、−COO−R30、または−OR30であり;
各mは独立して、0または1であり;
各nは独立して、0、1、2、3または4である)
の構造を有する化合物またはその薬学的に許容可能な塩。 - R1が、メチル、エチル、イソプロピル、t−ブチル、−CF3、メトキシ、エトキシ、ヒドロキシル、−OCF3 、ハロゲン、メチルチオおよび−SO2CH3からなる群より独立して選択される1つ以上の置換基で置換される、請求項2に記載の化合物。
- R1が、メチル、メトキシおよび−CF3からなる群より独立して選択される1つ以上の置換基で置換される、請求項3に記載の化合物。
- 請求項1〜6のいずれかに記載の化合物を少なくとも1つの薬学的に許容可能な担体、希釈剤または賦形剤とともに含む薬学的組成物。
- グルカゴン様ペプチド1受容体の活性化、増強またはアゴニズムのための、有効量の請求項1〜6のいずれかに記載の化合物を含む組成物または請求項8に記載の薬学的組成物であって、該組成物または該薬学的組成物は、該受容体と接触させられることを特徴とする、組成物。
- グルカゴン様ペプチド1(GLP−1)受容体の活性化、増強またはアゴニズムを必要とする被験体における活性化、増強またはアゴニズムのための組成物であって、該組成物は、
式I
X1A、X1B、X2A およびX2Bは各々、CHであり;
R 4は、H、アルキル、1つ以上のR43 で置換されたアルキル、ハロゲン、ペルハロアルキル、ペルハロアルコキシ、−CN、−OR40 または−NR41R42であり;
W1は−L 1 −CH 2 −R 1 であり;
L1は、−NH−C(O)−であり;
R1は、R13 であり;
R10、R11およびR12はそれぞれ独立して、Hまたはアルキルであり;
R13は、フェニルであり(ここで、R13の任意の環原子が1つ以上のR14またはR15で任意に置換されていてもよい);
各R14は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、−OR10、−(CH2)n−COOR10、−SR10、−SO−R10、−SO2R10、−(CH2)n−NR11R12、−NHCO(CH2)n−R12、−N(R11)CO(CH2)n−R12、または−NH(CH2)n−R12であり;
各R15は、シクロアルキル、ヘテロシクリルアルキル、アリール、ヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり(ここで、R15の任意の環原子が1つ以上のR14で任意に置換されていてもよい);
R 5は独立して、H、アルキル、1つ以上のR53 で置換されたアルキル、ハロゲン、ペルハロアルキル、ペルハロアルコキシ、−CN、−OR50もしくは−NR51R52 であり;
W2は−L 2 −R 2 であり;
L2は、1,2,4−オキサジアゾール−3−イルであり;
R2は、R26、−O−(CH2)n−R26、R23または−L 4−R23であり;
L4は、−O−(CH2)n−、−C≡C−、−C(O)NR20−(CH2)n−、−N(R20)−C(O)−(CH2)n−、−N(R20)−S(O2)−、−S(O2)−NR20−、またはシクロプロピレンであり;
各R20は独立して、Hまたはアルキルであり;
R23は、シクロアルキル、ヘテロシクリルアルキル、アリール、ヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であるか、あるいはR23とR20が、これらが結合するN原子とともに、任意にアリールまたはヘテロアリールと縮合した複素環を形成しており(ここで、R23の任意の環原子が1つ以上のR24で任意に置換されていてもよく、R23の1つの環原子が−L 3−R25で任意に置換されている);
各R24は独立して、H、ハロ、アルキル、ヒドロキシ、オキソ、シアノ、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、ニトロまたはアミノ、−O−(CH2)n−R21、−(CH2)n−O−R21、−O−(CH2)n−O−R21、−(CH2)n−NR21R22、−(CH2)n−N(R21)CO(CH2)n−R21、−(CH2)n−N(R21)SO2(CH2)n−R21、−(CH2)n−SO2−N(R21)−(CH2)n−R21、−(CH2)n−CO(CH2)n−R21、−(CH2)m−COO−R21、−O−(CH2)n−COO−R21または−(CH2)m−OCO−R21 であり;
R21およびR22はそれぞれ独立して、H、アルキル、または−(CH2)n−COOHであるか、あるいはR 21 およびR 22 が、それらが結合する窒素原子とともに3〜7員の複素環を形成し;
L3は、無、−O−、−(CH2)n−O−(CH2)n−、または−(CH2)n−NR20−(CH2)n−であり;
各R25は独立して、シクロアルキル、ヘテロシクリルアルキル、アリールもしくはヘテロアリール、またはこのような環部分のいずれか2つの縮合二環であり(ここで、R25の任意の環原子が1つ以上のR24で任意に置換されていてもよい);
R 26は、H、アルキル、アルコキシ、オキソ、ヒドロキシまたはヒドロキシ置換アルキルであり;
Yは、−C(O)−、−CH2−、−C(O)−CH2−、または−CH2−C(O)−であり;
Zは、−(CH2)n−C(O)−R3、−(CH2)n−R3、−R34−C(O)−R3、またはHであり;
R34は、シクロアルキル、ヘテロシクリルアルキル、アリール、またはヘテロアリールであり(ここで、R34の任意の環原子が1つ以上のR35で任意に置換されていてもよい);
各R35は独立して、H、アルキル、ハロ、ヒドロキシ、シアノ、アルコキシまたはペルハロアルキルであり;
R3は、−OR30、−NR31R32 、または−(CO)NHSO2R30 であり;
各R30は独立して、Hまたはアルキルであり;
R31およびR32はそれぞれ独立して、Hまたは1つ以上のR33で任意に置換されたC1−C6アルキルであるか、あるいはR 31 およびR 32 が、それらが結合するN原子とともに3〜7員の複素環を形成し;
各R33は独立して、ハロ、ヒドロキシル、アルコキシ、ペルハロアルキル、ペルハロアルコキシ、カルボキシル、−COO−R30、または−OR30であり;
R40およびR50はそれぞれ独立して、Hまたはアルキルであり;
R41およびR42はそれぞれ独立して、H、アルキル、−(CH2)n−COO−R40、−C(O)−R40、アリール、またはヘテロアリールであるか、あるいはR 41 およびR 42 が、それらが結合するN原子とともに3〜7員の複素環を形成し;
R51およびR52はそれぞれ独立して、Hまたはアルキル、−(CH2)n−COO−R50、−C(O)−R50、アリール、ヘテロアリールであるか、あるいはR 51 およびR 52 が、それらが結合するN原子とともに3〜7員の複素環を形成し;
各R43は独立して、H、ハロ、ヒドロキシル、−NR41R42、またはアルコキシであり;
各R53は独立して、H、ハロ、ヒドロキシル、−NR51R52、またはアルコキシであり;
kは1、2、3または4であり;
各mは独立して、0または1であり;
各nは独立して、0、1、2、3または4である)
の構造を有する化合物またはその薬学的に許容可能な塩を含む薬学的組成物を含む組成物。 - 前記被験体がヒトである、請求項10に記載の組成物。
- グルカゴン様ペプチド1受容体の活性化、増強またはアゴニズムが医学的に指示される患者の異常状態の処置のための組成物であって、有効量の請求項1〜6のいずれかに記載の化合物を含み、該患者に有益な効果を提供するのに十分な頻度および継続時間で投与されることを特徴とする、組成物。
- 前記異常状態が、1型糖尿病、2型糖尿病、妊娠糖尿病、肥満、食欲過多、満腹感不足、または代謝性障害を含む、請求項12に記載の組成物。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161491446P | 2011-05-31 | 2011-05-31 | |
US61/491,446 | 2011-05-31 | ||
US201161535750P | 2011-09-16 | 2011-09-16 | |
US61/535,750 | 2011-09-16 | ||
US201161569759P | 2011-12-12 | 2011-12-12 | |
US61/569,759 | 2011-12-12 | ||
PCT/US2012/040250 WO2012166951A1 (en) | 2011-05-31 | 2012-05-31 | Novel glp-1 receptor stabilizers and modulators |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016061862A Division JP2016128509A (ja) | 2011-05-31 | 2016-03-25 | 新規glp−1受容体安定剤および調節剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014527027A JP2014527027A (ja) | 2014-10-09 |
JP2014527027A5 JP2014527027A5 (ja) | 2016-05-19 |
JP6007417B2 true JP6007417B2 (ja) | 2016-10-12 |
Family
ID=47259864
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014513706A Expired - Fee Related JP6007417B2 (ja) | 2011-05-31 | 2012-05-31 | 新規glp−1受容体安定剤および調節剤 |
JP2016061862A Pending JP2016128509A (ja) | 2011-05-31 | 2016-03-25 | 新規glp−1受容体安定剤および調節剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016061862A Pending JP2016128509A (ja) | 2011-05-31 | 2016-03-25 | 新規glp−1受容体安定剤および調節剤 |
Country Status (7)
Country | Link |
---|---|
US (2) | US9278910B2 (ja) |
EP (1) | EP2713722B1 (ja) |
JP (2) | JP6007417B2 (ja) |
DK (1) | DK2713722T3 (ja) |
ES (1) | ES2634716T3 (ja) |
PT (1) | PT2713722T (ja) |
WO (1) | WO2012166951A1 (ja) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8501982B2 (en) | 2010-06-09 | 2013-08-06 | Receptos, Inc. | GLP-1 receptor stabilizers and modulators |
DK2713722T3 (en) | 2011-05-31 | 2017-07-03 | Celgene Int Ii Sarl | Newly known GLP-1 receptor stabilizers and modulators |
RU2634896C2 (ru) | 2011-12-12 | 2017-11-08 | Селджин Интернэшнл Ii Сарл | Новые модуляторы рецептора glp-1 |
SI2861579T1 (en) | 2012-05-15 | 2018-05-31 | Novartis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
BR112014027584B1 (pt) | 2012-05-15 | 2023-01-24 | Novartis Ag | Uso de inibidores da atividade de abl1, abl2 e bcr-abl1, e composição farmacêutica |
AU2013261128B2 (en) | 2012-05-15 | 2015-11-12 | Novartis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
WO2013171642A1 (en) | 2012-05-15 | 2013-11-21 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
ES2864349T3 (es) | 2013-06-11 | 2021-10-13 | Receptos Llc | Nuevos moduladores del receptor GLP-1 |
EP3054936B1 (en) | 2013-10-10 | 2023-10-18 | Eastern Virginia Medical School | 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as 12-lipoxygenase inhibitors |
KR102564946B1 (ko) | 2014-07-25 | 2023-08-08 | 리셉토스 엘엘씨 | 신규 glp-1 수용체 조절제 |
SG10201900631TA (en) | 2014-08-01 | 2019-02-27 | Nuevolution As | Compounds active towards bromodomains |
EP3194403B1 (en) | 2014-09-15 | 2019-02-06 | Rugen Holdings (Cayman) Limited | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists |
CA2969944A1 (en) | 2014-12-10 | 2016-06-16 | Celgene International Ii Sarl | Glp-1 receptor modulators |
EP3253761A4 (en) | 2015-02-04 | 2018-06-20 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists |
KR102613179B1 (ko) * | 2015-06-01 | 2023-12-14 | 뤼겐 홀딩스 (케이맨) 리미티드 | Nr2b nmda 수용체 길항제로서의 3,3-디플루오로피페리딘 카바메이트 헤테로사이클릭 화합물 |
EP3101007A1 (en) * | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
US10584118B2 (en) | 2015-06-22 | 2020-03-10 | Actelion Pharmaceuticals Ltd | NADPH oxidase 4 inhibitors |
ES2899906T3 (es) | 2015-07-06 | 2022-03-15 | Alkermes Inc | Inhibidores bicíclicos de histona desacetilasa |
EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
HUE050030T2 (hu) * | 2015-10-02 | 2020-11-30 | Syngenta Participations Ag | Mikrobiocid oxadiazol-származékok |
WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
MX2018007774A (es) | 2015-12-22 | 2018-11-09 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
CA3006911A1 (en) | 2015-12-22 | 2017-06-29 | Syngenta Participations Ag | Pesticidally active pyrazole derivatives |
AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
CN109890819B (zh) | 2016-06-20 | 2022-11-22 | 因赛特公司 | 作为免疫调节剂的杂环化合物 |
EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
EP3504198B1 (en) | 2016-08-29 | 2023-01-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2018098128A1 (en) | 2016-11-22 | 2018-05-31 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
US11046683B2 (en) | 2016-12-15 | 2021-06-29 | Ono Pharmaceutical Co., Ltd. | Activator of TREK (TWIK RElated K+ channels) channels |
WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
PE20191532A1 (es) | 2016-12-22 | 2019-10-23 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
LT3558990T (lt) | 2016-12-22 | 2022-12-27 | Incyte Corporation | Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai |
ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
WO2018132533A1 (en) | 2017-01-11 | 2018-07-19 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
CA3056886A1 (en) * | 2017-03-21 | 2018-09-27 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
JP7116745B2 (ja) * | 2017-04-28 | 2022-08-10 | レセプトス・リミテッド・ライアビリティ・カンパニー | 新規なglp-1受容体モジュレーター |
JOP20200001A1 (ar) | 2017-07-11 | 2022-10-30 | Vertex Pharma | كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم |
CA3071861A1 (en) | 2017-08-07 | 2019-02-14 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
SG11202001684PA (en) | 2017-10-06 | 2020-03-30 | Forma Therapeutics Inc | Inhibiting ubiquitin specific peptidase 30 |
MX2020010321A (es) | 2018-03-30 | 2021-01-08 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
MX2020012045A (es) | 2018-05-11 | 2021-03-29 | Incyte Corp | Derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores de ligando 1 de muerte programada (pd-l1). |
WO2020072964A1 (en) | 2018-10-05 | 2020-04-09 | Forma Therapeutics, Inc. | Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
MX2022001671A (es) | 2019-08-09 | 2022-05-13 | Incyte Corp | Sales de un inhibidor de pd-1/pd-l1. |
AR120109A1 (es) | 2019-09-30 | 2022-02-02 | Incyte Corp | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores |
CN114829366A (zh) | 2019-11-11 | 2022-07-29 | 因赛特公司 | Pd-1/pd-l1抑制剂的盐及结晶形式 |
CN112812077B (zh) * | 2019-11-18 | 2023-08-22 | 中国科学院上海药物研究所 | 苯甲酰胺类化合物及其制备方法、药物组合物和用途 |
AU2020397059A1 (en) | 2019-12-06 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
CA3171979A1 (en) | 2020-03-27 | 2021-09-30 | Josep Bassaganya-Riera | Plxdc2 ligands |
KR102576148B1 (ko) * | 2020-04-13 | 2023-09-07 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
WO2022099071A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
IL308953A (en) | 2021-06-04 | 2024-01-01 | Vertex Pharma | N-Hydroalkyl(Hetero)Aryl)Tetrahydrofuran Carboxamides as Natrene Channel Modulators |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1062206B (it) | 1974-02-01 | 1983-09-20 | Rotta Research Lab S P A A S | Derivati della tirosina attivi sulla muscolatura liscia |
DE2423536A1 (de) | 1974-05-15 | 1975-11-27 | Bayer Ag | 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
WO1998030231A1 (en) | 1997-01-07 | 1998-07-16 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the reduction of food intake |
CN1265672A (zh) | 1997-07-31 | 2000-09-06 | 伊兰药品公司 | 能抑制由vla-4介导的白细胞粘连的磺酰化二肽化合物 |
US6583139B1 (en) | 1997-07-31 | 2003-06-24 | Eugene D. Thorsett | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
DK1005445T3 (da) | 1997-08-22 | 2004-10-04 | Hoffmann La Roche | N-alkanoylphenylaninderivater |
US6191171B1 (en) * | 1997-11-20 | 2001-02-20 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
BR9916027A (pt) | 1998-12-07 | 2001-08-28 | Sod Conseils Rech Applic | Análogos de glp-1 |
CN101181236A (zh) | 1999-01-14 | 2008-05-21 | 安米林药品公司 | 新型exendin激动剂制剂及其给药方法 |
TW200514783A (en) | 1999-09-22 | 2005-05-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
EE04877B1 (et) | 2000-03-07 | 2007-08-15 | Aventis Pharma Deutschland Gmbh | Asendatud 3-fenl-5-alkoks-1,3,4-oksadiasol-2-oon, selle valmistamine ja kasutamine hormoontundlikku lipaasi prssivas ravimis ning seda sisaldav suhkurt?ve ravim |
AU2002350217A1 (en) | 2001-12-04 | 2003-06-17 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
AU2003211560A1 (en) | 2002-02-20 | 2003-09-09 | Ajinomoto Co., Inc. | Novel phenylalanine derivative |
US20070276034A1 (en) * | 2002-05-31 | 2007-11-29 | Luke Esposito | Compounds, compositions and methods for the treatment of synucleinopathies |
WO2004022561A1 (en) | 2002-09-04 | 2004-03-18 | Schering Corporation | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors |
PL224879B1 (pl) * | 2002-09-04 | 2017-02-28 | Pharmacopeia Drug Discovery Inc | Pirazolo [1,5-a] pirymidynowy związek, jego zastosowanie do wytwarzania leku oraz zawierająca go farmaceutyczna kompozycja |
US20040152750A1 (en) * | 2002-12-20 | 2004-08-05 | Kodra Janos Tibor | Novel glucagon antagonists |
BRPI0411412A (pt) | 2003-06-13 | 2006-07-25 | S A L V A T Lab Sa | novas benzamidas como moduladores ppary |
EP2615087A3 (en) | 2003-12-22 | 2013-08-07 | Ajinomoto Co., Inc. | Phenylalanine derivatives |
WO2005077915A1 (en) | 2004-02-10 | 2005-08-25 | Janssen Pharmaceutica, N.V. | Pyridazinones as antagonists of a4 integrins |
WO2006117743A1 (en) | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Substituted aromatic compounds as antidiabetic agents |
EP1899304A1 (en) | 2005-05-23 | 2008-03-19 | Arena Pharmaceuticals, Inc. | 5-amino-1h-pyrazole-3-carboxylic acid derivatives as agonists for the g-protein coupled receptor (gpcr) rup38 for the treatment of metabolic-related disorders thereof |
US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
EP1878730A1 (en) | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same |
US7816324B2 (en) | 2007-03-13 | 2010-10-19 | Board Of Regents, The University Of Texas System | Composition and method for the treatment of diseases affected by a peptide receptor |
WO2008149382A1 (en) | 2007-06-08 | 2008-12-11 | Advinus Therapeutics Private Limited | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application |
JP2010148234A (ja) | 2008-12-18 | 2010-07-01 | Seiko Epson Corp | 残留電荷放電回路および電源用半導体装置 |
WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
US8501982B2 (en) | 2010-06-09 | 2013-08-06 | Receptos, Inc. | GLP-1 receptor stabilizers and modulators |
DK2713722T3 (en) | 2011-05-31 | 2017-07-03 | Celgene Int Ii Sarl | Newly known GLP-1 receptor stabilizers and modulators |
RU2634896C2 (ru) | 2011-12-12 | 2017-11-08 | Селджин Интернэшнл Ii Сарл | Новые модуляторы рецептора glp-1 |
ES2864349T3 (es) | 2013-06-11 | 2021-10-13 | Receptos Llc | Nuevos moduladores del receptor GLP-1 |
KR102564946B1 (ko) | 2014-07-25 | 2023-08-08 | 리셉토스 엘엘씨 | 신규 glp-1 수용체 조절제 |
-
2012
- 2012-05-31 DK DK12793320.8T patent/DK2713722T3/en active
- 2012-05-31 EP EP12793320.8A patent/EP2713722B1/en active Active
- 2012-05-31 JP JP2014513706A patent/JP6007417B2/ja not_active Expired - Fee Related
- 2012-05-31 US US14/122,176 patent/US9278910B2/en not_active Expired - Fee Related
- 2012-05-31 ES ES12793320.8T patent/ES2634716T3/es active Active
- 2012-05-31 WO PCT/US2012/040250 patent/WO2012166951A1/en active Application Filing
- 2012-05-31 PT PT127933208T patent/PT2713722T/pt unknown
-
2016
- 2016-01-15 US US14/997,364 patent/US9700543B2/en active Active
- 2016-03-25 JP JP2016061862A patent/JP2016128509A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20160310471A1 (en) | 2016-10-27 |
US9700543B2 (en) | 2017-07-11 |
EP2713722A1 (en) | 2014-04-09 |
JP2016128509A (ja) | 2016-07-14 |
PT2713722T (pt) | 2017-06-27 |
ES2634716T3 (es) | 2017-09-28 |
WO2012166951A9 (en) | 2013-02-21 |
US9278910B2 (en) | 2016-03-08 |
DK2713722T3 (en) | 2017-07-03 |
US20140336185A1 (en) | 2014-11-13 |
EP2713722A4 (en) | 2014-11-26 |
WO2012166951A1 (en) | 2012-12-06 |
EP2713722B1 (en) | 2017-03-15 |
JP2014527027A (ja) | 2014-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6007417B2 (ja) | 新規glp−1受容体安定剤および調節剤 | |
CA2857197C (en) | Novel glp-1 receptor modulators | |
EP3008056B1 (en) | Novel glp-1 receptor modulators | |
JP2013530963A (ja) | 新規のglp−1受容体安定化薬および調節薬 | |
EP3230276B1 (en) | Glp-1 receptor modulators | |
NZ626122B2 (en) | Carboxylic acid derivatives comprising four cycles acting as glp-1 receptor modulators for therapy of diseases such as diabetes | |
NZ715006B2 (en) | Novel glp-1 receptor modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140701 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150529 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150529 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20151029 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151126 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160223 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20160325 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160803 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160816 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6007417 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
LAPS | Cancellation because of no payment of annual fees |